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ABSTRACT

Breast and cervical cancer are two common cancers that severely endanger
women’s health. The fatality rates of breast and cervical cancer are ranked first and fifth,
respectively, in cancer related deaths in women worldwide. Continuous dedication to
cancer research is urgently required to elucidate the cancer cell survival mechanism that
is responsible for disease aggressiveness and poor prognosis.
Emerging data indicate that Notch-1 is aberrantly regulated in human cervical and
ER- breast cancer and inhibiting Notch-1 sensitizes cancer cells to apoptosis. However,
the mechanism by which Notch-1 promotes cell survival is not known. NF-κB is also
deregulated in these two cancers and might be the downstream signaling effector of
Notch-1 to modulate cell survival and apoptosis. Here, we show that Notch-1 may
provide cells with survival signal by activating NF-κB activity in cervical and ER- breast
cancer.
First, we showed that Notch-1 activates and is required to maintain NF-κB
activity in cervical cancer CaSki cells and ER- breast cancer MDA-MB-231 cells. Then,
we found that Notch-1 activates NF-κB activity by interacting with IKKα/β and
regulating IKKα/β kinase activity in CaSki cells stimulated with TNF-α.
Lastly, we demonstrated that Notch-1 activates NF-κB dependent gene expression
in MDA-MB-231 cells through an Akt/IKK dependent pathway. We showed that Notch-1
xvi

and IKKα are required for the expression of a subset of NF-κB dependent genes. Notch
activation mediated by Jagged-1 or EDTA activates Akt, which in turn activates the IKK
complex. Notch activation mediated by Jagged-1 also induces NF-κB subunits, Pol II and
IKKα recruitment to the NF-κB dependent gene promoters. Inhibiting Akt
pharmacologically or genetically reduces the IKK activation and decreases NF-κB
subunits, Pol II and IKKα recruitment to the NF-κB dependent gene promoters.
In summary, we showed that Notch-1 activates NF-κB activity in both cervical
and ER- breast cancer cells, and we explored similarities and differences in the
underlying mechanisms in the two cell types. Potentially, this study will provide a
molecular rationale for targeting Notch-1, Akt and NF-κB in cervical and ER- breast
cancer in the clinic.

xvii

CHAPTER I
INTRODUCTION

A. Background

1. Overview of cervical cancer and breast cancer

Cervical cancer is the second most frequently diagnosed neoplasm in women
worldwide, constituting ~12% of all female cancers and causing ~250,000 deaths
annually. Incidences of cervical cancer are higher in developing countries compared to
developed countries (Sankaranarayanan et al., 2006). Persistent human papillomavirus
(HPV) infections are now recognized as the major cause of cervical cancer. HPV types
16 and 18 together cause about 70% of cervical cancers (Munoz et al., 2003). The
vaccine effective against these two HPVs has been licensed in the U.S. and the EU.
Cervical cancer was once the leading cause of death for women in the United
States. During the past few decades, largely due to widespread use of the Papanicolaou
test, incidence and mortality from cervical cancer have declined significantly. However,
pressing demands still exist for developing more specific and more accurate screening
tests. Understanding cervical cancer neoplastic formation will lay the foundation for
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translating those molecular knowledge into developing more effective screening tests and
treatments. There are several signal transduction pathways known to be deregulated in
cervical cancer cells. Notch-1 and Nuclear Factor-kappa B (NF-κB) signaling pathways
are two of those identified. In this thesis, we focused on the cross talk of Notch-1 and
NF-κB signaling pathways in cervical cancer CaSki cells and the underlying mechanism
whereby Notch-1 activates NF-κB.
Currently, breast cancer, particularly estrogen receptor alpha negative (ER-)
breast cancer, has taken over cervical cancer and has become the leading cause of cancer
related mortality in women worldwide (Wildiers et al., 2007). It is estimated that each
year this disease is diagnosed in over one million people worldwide and is the cause of
more than 400,000 deaths (O'Driscoll and Clynes, 2006). The incidence of breast cancer
has been increasing steadily from an incidence of 1:20 in 1960 to 1:8 women today. Early
detection methods such as mammography and application of targeted therapy have
improved the outlook of many breast cancer patients. However the morbidity and
mortality rate remain high, partially because of low response rate in some subsets of
breast cancers and the development of resistance to therapeutic drugs. Considerable effort
has been dedicated into looking at the underlying mechanisms contributing to the low
response rate and drug resistance. Not only in cervical cancer, but also in breast cancer,
Notch-1 and NF-κB signaling pathways have been shown to be associated with poor
outcome and drug resistance. In this thesis, we investigated the interplay of these two
deregulated pro-proliferative signaling transduction pathways and the underlying
mechanism responsible for their interaction in breast cancer.
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Breast cancers can be classified into two groups: Estrogen Receptor positive (ER+)
breast cancer, making up 70% of all breast cancers, or Estrogen Receptor negative (ER-)
ones, constituting the remainder. Estrogen induces tumor cell growth through binding to
ER and initiating hormone responsive gene expressions. The estrogen downstream
proteins presumably promote mammary epithelial cell proliferation (Jordan, 1995). The
current anti-hormone treatment tamoxifen, inhibits breast tumor proliferation by binding
to ER but not conferring it into an active conformation, thus blocking downstream events.
However, since tamoxifen targets the ER, it is not effective against ER- breast cancer.
Breast cancers usually progress from benign, ER+, estrogen dependent, noninvasive
tumors to malignant, ER-, estrogen independent, invasive and metastatic ones (Clarke et
al., 1990). ER- breast cancers are therefore clinically more aggressive and more difficult
to treat than ER+ breast tumors (Jemal et al., 2002). Therefore in this thesis, we focused
on the regulation of Notch-1 on pro-survival NF-κB signaling pathway in ER- breast
cancer.

2. Notch-1 in cervical cancer and breast cancer

Emerging evidence has shown that Notch-1 and its ligands and targets have been
associated with transformation of many types of tumors including cervical and breast
cancer (Miele, 2006). Notch is a single-pass transmembrane receptor that participates in
communication between adjacent cells (Nickoloff et al., 2002; Miele et al., 2006; Miele,
2006).The interaction between Notch and its ligands in a neighboring cell triggers Notch
receptor activation. This conformational change resulting from ligand-receptor
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interaction initiates two cleavages on Notch receptor, releasing an intracellular domain of
Notch, (NIC) (Saxena et al., 2001). After NIC is released from the plasma membrane, it
is translocated into the nucleus where it modulates gene expression primarily, but not
exclusively, by binding to a ubiquitous transcription factor CBF-1 (Artavanis-Tsakonas et
al., 1999). Notch-1 converts CBF-1 from a constitutive repressor into an activator by
displacing a panel of co-repressors and recruiting a co-activator complex (Kao et al.,
1998; Hsieh et al., 1999; Kurooka and Honjo, 2000; Oswald et al., 2001; Wu et al., 2000).
The target genes of Notch include hairy enhancer of split genes (HES) and HES-related
repressor protein (HERP) (Iso et al., 2003), HEY family (Maier and Gessler, 2000),
which are helix-loop-helix transcriptional regulators modulating differentiation, cell cycle
mediator p21 (Rangarajan et al., 2001), and cyclin D (Ronchini and Capobianco, 2001)
as well as NF-κB family (Cheng et al., 2001) and PPAR family (Garces et al., 1997;
Nickoloff et al., 2002) transcription factors.
Accumulated evidence shows that Notch-1 is deregulated in cervical as well as
breast cancer. Increased expression of Notch-1 and Notch ligands were reported in
cervical carcinomas (Zagouras et al., 1995; Daniel et al., 1997; Gray et al., 1999).
Accumulation of Notch-1 and its ligand Jagged1 and downregulation of Manic Fringe, a
negative regulator of Notch signaling coincided with the progression of high-grade
precursor lesions to invasive cervical cancers (Veeraraghavalu et al., 2004). More
importantly, Notch-1 was shown to cooperate with HPV oncoproteins in transforming
immortalized human keratinocytes (Rangarajan et al., 2001; Ramdass et al., 2006).
HPV16 oncoproteins E6 and E7 increased Notch-1 levels and CBF-1 transcriptional
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activity in primary mouse embryo cells (Weijzen et al., 2003). Taken together, Notch-1 is
oncogenic in cervical cancer.
The accumulation of intracellular Notch and elevated Notch signaling were also
observed in a variety of human breast carcinomas (Reedijk et al., 2005; Stylianou et al.,
2006). Our lab has confirmed that Notch expression was deregulated in human breast
cancer as opposed to normal breast cells. Ductal and lobular carcinomas consistently
expressed high levels of Notch-1 and Notch-4 as compared to normal breast tissue. In
addition, high level expression of Notch-1 or Notch-1 ligand Jagged-1 predicted poor
overall survival in breast cancer patients，combination of both at high levels indicated
even worse outlook (Reedijk et al., 2005; Dickson et al., 2007). Also, increased Notch
signaling was sufficient to transform normal breast epithelial cells (Reedijk et al., 2005).
Overall, the data support the idea that Notch plays an oncogenic role in human breast
cancer. Recently, we and others have observed that high levels of Notch-1 and Jagged-1
were mostly found in ER- basal phenotype breast cancer (ER-, progesterone receptor
(PR)-, Her2-) (Rizzo et al., 2008). We chose the breast cancer cell line MDA-MB-231
cells, which are ER- , PR- and Her2-, as our model system to study Notch-1 signaling.
There is increasing evidence that inhibition of Notch-1 sensitizes cervical and
breast cancer cells to apoptosis, causes cell cycle arrest and decreases cellular
transformation. Inhibiting Notch signaling by siRNA in CaSki cervical cancer cells
abolished proliferation and anchorage-independent growth in vitro (Weijzen et al., 2002)
and completely blocked the growth of CaSki xenografts in vivo (Weijzen et al., 2003).
Inhibition of Notch by Gamma-secretase inhibitor (GSI) suppressed breast tumors growth
(Pece et al., 2004) and reverted the transformed phenotype of human breast cancer cell
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lines, including the ER- breast cancer cell line MDA-MB-231 (Stylianou et al., 2006).
Our lab also showed that Notch-1 knockdown by siRNA or GSI caused G2 arrest and
induced apoptosis in breast cancer cells. In vivo, GSI arrested the growth of MDA-MB231 tumors and in combination with tamoxifen, caused regression of T47D:A18 (ER+
breast cancer cell) tumors (Rizzo et al., 2008). All these suggest that Notch signaling is a
potential therapeutic target in cervical and breast cancer.
To date, the mechanism whereby Notch-1 promotes cell survival and/or
proliferation and transformation is not clear. Reports suggest that Notch-1 may contribute
to cell survival and proliferation via NF-κB dependent pathway in cervical and breast
cancer. In this thesis, we will show that Notch-1 promotes cell survival in part by
activating NF-κB activity in cervical and ER- breast cancer.

3. NF-κB in cervical cancer and breast cancer

NF-κB is a family of transcription factors with a critical role in regulating
inflammation, cell survival, cell differentiation, and cell proliferation. The NF-κB
subunits are inactive in the cytoplasm as a result of binding to inhibitory proteins of the
IκB family (IκBs). In response to numerous stimuli: cytokines, chemokines, mitogens,
bacterial and viral infection, an IKB kinase (IKK) complex is activated by IKK kinases
(Karin, 1999). Activated IKK complex phosphorylates IκBs, leading to 26s proteasome
mediated degradation of IκB. Degradation of IκB releases NF-κB, enabling it to
translocate to the nucleus and rapidly induce a variety of genes encoding matrix

7
metalloproteinases, inflammatory and chemotactic cytokines, and antiapoptotic proteins
(Li and Verma, 2002; Karin and Lin, 2002; Karin et al., 2002).
NF-κB is a major survival pathway that is highly relevant to cervical cancer.
Previous studies have shown that NF-κB is constitutively activated in human cervical
squamous cell carcinomas as compared to normal cervical epithelium. Increased nuclear
staining of p50 and p65 and expression of NF-κB target genes have been detected in
cervical cancer. Constitutive activation of NF-κB with nuclear accumulation of p50 and
p65 is associated with cervical cancer progression (Nair et al., 2003; Prusty et al., 2005).
Blocking NF-κB in cervical cancer cells may not only help eradicate tumor cells but also
increase sensitivity to other conventional therapies. The cytotoxicity of arsenic trioxide
(Woo et al., 2004; Wei et al., 2005) and celecoxib (Kim et al., 2004) on cervical cancer
cells is mediated in part by NF-κB inhibition. Inhibition of NF-κB sensitizes cervical
cancer cells to cisplatin induced apoptosis (Venkatraman et al., 2005) and enhances
radiosensitivity of certain human cervical carcinoma cancer cells in vitro (Kamer et al.,
2009).
In addition to cervical cancer, NF-κB was found to be highly active in ER- breast
cancer cell lines as well as in ER- primary breast tumors. Constitutive DNA binding of
NF-κB and elevated NF-κB concentration were also detected in extracts from poorly
differentiated ER- primary tumors (Nakshatri et al., 1997; Bhat-Nakshatri et al., 1998;
Biswas et al., 2000). Elevated NF-κB activation in ER- breast cancer has been suggested
to be responsible for chemoresistance and metastatic growth. It was shown that active
NF-κB protects the cells from apoptosis induced by TNF-α, ionizing radiation, or
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daunorubicin. The protection resulted in radiation and drug resistance (reviewed in
(Nakshatri et al., 1997).
NF-κB has been considered a potential therapeutic target for cervical and ERbreast cancer (Nakshatri et al., 1997; Biswas et al., 2000; Biswas et al., 2001; Biswas et
al., 2004; Huang et al., 2009). Better understanding of the NF-κB signaling pathway will
facilitate the development of more effective therapy for cervical and ER- breast cancer.

B. Specific Aims

Overall, emerging evidence indicated that Notch-1 was aberrantly regulated in
human cervical and ER- breast cancer and inhibiting Notch-1 sensitized cancer cells to
apoptosis. However, the mechanism whereby Notch-1 promotes cell survival and/or
proliferation and transformation is not clear. Accumulating reports suggest that Notch-1
may contribute to cell survival and proliferation via the NF-κB dependent pathway in
cervical and breast cancer, since Notch-1 and NF-κB are both deregulated in these two
cancers and NF-κB provides pro-survival signal for cancer cells. It was shown that
activated Notch signaling was accompanied by elevated NF-κB activity as determined by
immunohistochemistry from cervical cancer patients’ samples. Constitutive activation of
NF-κB with nuclear accumulation of p50 and p65 has been described to be associated
with cervical cancer progression (Nair et al., 2003; Prusty et al., 2005). Aberrantly
regulated Notch and NF-κB activity were also concurrently found in ER- breast cancer.
Notch-1 and NF-κB activity were highly active in ER- breast cancer cell lines as well as
ER- breast tumors as compared to ER+ counterparts. Elevated NF-κB activation in ER-
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breast cancer has been suggested to be responsible for chemoresistance and metastatic
growth. Here, we hypothesize that Notch-1 promotes cell survival by activating NF-κB
activity in cervical and ER- breast cancer.
To test this hypothesis we had 3 aims.
Aim 1: To determine whether Notch-1 activates NF-κB in cervical and ER- breast
cancer.
Aim 2: To characterize the mechanism by which Notch-1 activates NF-κB in
cervical cancer Caski cells.
Aim 3: To elucidate the mechanism by which Notch-1 activates NF-κB dependent
gene expression in ER- breast cancer MDA-MB-231 cells.
In Aim 1, we showed that Notch-1 activates and is required to maintain
constitutively active NF-κB activity in cervical cancer CaSki cells and ER- breast cancer
MDA-MB-231 cells. NF-κB activity was determined by luciferase reporter assays under
the conditions of either over-expressing Notch-1 or silencing Notch-1 by siRNA in both
cervical cancer CaSki and ER- breast cancer MDA-MB-231 cells. It was found that
down-regulation of Notch-1 causes a decrease in NF-κB dependent transcription activity
and activation of Notch-1 leads to an increase in NF-κB activity in both cells.
In Aim 2, we showed that Notch-1 interacts with IKK complex and activating
IKKα/β kinase activity in CaSki cells. The interaction between Notch-1 and IKK
complex is shown by traditional Co-IP and rellina luciferase Co-IP. By Using in vitro
kinase assay and western blot of phosphorylation of endogenous IκBα, we showed that
IIKKα/β kinase activity induced by TNF-α is inhibited by either Notch-1 siRNA or GSI
treatment.
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In Aim 3, we were trying to elucidate the mechanism by which Notch-1 activates
NF-κB dependent gene expression in ER- breast cancer MDA-MB-231 cells. We initially
tested whether Notch-1 activates NF-κB by interacting with IKK complex and activating
IKKα/β kinase activity the same as in cervical cancer cells, however, we could not detect
a Notch-1/IKK physical interaction.
In order to explore the mechanism accounting for Notch-1 regulation of NF-κB in
ER- breast cancer, we started gene expression studies in ER- breast cancer MDA-MB231 cells. We found that both Notch-1 and IKKα are essential for basal and stimulated
expression of some NF-κB dependent genes. As a well-known transcription factor,
Notch-1 activates expression of target genes by binding to CBF-1, a DNA binding protein,
and converting CBF-1 from a repressor to an activator. Binding of Notch-1 to CBF-1
facilitates the recruitment of transcription coactivators to the target gene promoters. Both
Notch-1 and IKKα have nuclear functions. On the cIAP-2 promoter, IKKα has been
shown to have nuclear kinase function to activate gene transcription by phosphorylating
corepressor SMRT (silencing mediator of retinoid and thyroid hormone receptors)
(Hoberg et al., 2004; Hoberg et al., 2006). We found that Notch-1 and IKKα were
recruited to NF-κB dependent genes cIAP-2 and IκBα promoter in Caski cells.
Furthermore, the IKKα recruitment was Notch-1 dependent on both promoters (Song et
al., 2008). This promoted us to hypothesize that Notch-1 and IKKα together may exert
regulation on NF-κB dependent gene promoters in MDA-MB-231 cells. Therefore, we
explored the recruitment of Notch-1, IKKα and NF-κB on NF-κB dependent gene
promoters in MDA-MB-231 cells by chromatin immunoprecipitation assays. We found
that NF-κB subunits, Notch-1 and IKKα were recruited to NF-κB dependent gene
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promoters however; Notch-1 was recruited later than NF-κB subunits and IKKα. NF-κB
subunits and IKKα occupancy were Notch-1 dependent, suggesting that Notch-1 activates
IKK complex and IKKα before being recruited to the promoter. What could be the
possible way that Notch-1 activates IKK complex and IKKα before the nuclear function?
Akt might be the IKK upstream kinase responsible for NF-κB activation mediated
by active Notch-1. Akt signaling pathway is involved in multiple cellular functions
including promoting cell growth, increasing glucose uptake and oxidation, cell cycle
progression and cell survival. Many studies showed that Notch-1 activates or is required
for activation of Akt pathway in various systems (Nair et al., 2003; Liu et al., 2006;
Graziani et al., 2008; Meng et al., 2009). Notch-1 has been shown to promote T-cell
precursors survival, inhibit and rescue apoptosis, sustain transformation, drive tumor
progression through a PI3K/Akt dependent pathway (Sade et al., 2004; Ciofani and
Zuniga-Pflucker, 2005; Nair et al., 2003; Liu et al., 2006; Perumalsamy et al., 2009). In
addition，NF-κB is an important downstream target of Akt activation. Akt promotes
transactivation potential and phosphorylation of NF-κB through IKK (Ozes et al., 1999;
Madrid et al., 2001). Akt is proposed to promote metastasis and angiogenesis through
IKK in a manner that depends on NF-κB activation (Agarwal et al., 2005). Therefore, it
is possible that Notch-1 activates NF-κB through Akt/IKK dependent pathway in MDAMB-231 cells.
We showed that Notch activation mediated by Jagged-1 activated the IKK
complex and induced phosphorylation and degradation of IκBα. We found that Akt was
upstream of IKK in the NF-κB activation pathway mediated by Jagged-1. Inhibiting Akt
pharmacologically or genetically reduced the IKK activation and decreased NF-κB
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subunits, Pol II and IKKα recruitment to NF-κB dependent gene promoters. In agreement
with the data from Notch-1 activation by Jagged-1, Notch-1 activation mediated by
EDTA activated Akt/IKK/NF-κB pathway as well. We found that Akt activation was
independent of canonical nuclear Notch-1 partner CBF-1, suggesting that cytoplasmic
Notch-1 might have a role in NF-κB activation through an Akt/IKK/ NF-κB axis.
In summary, we demonstrated that Notch-1 activates NF-κB activity in both
cervical and ER- breast cancer and we explored similarities and differences in the
underlying mechanisms in the two systems.

C. Significance of the study

The purpose of this work is to identify and characterize the relationship between
two signaling pathways: Notch-1 and NF-κB in cervical and ER- breast cancer. These
two pathways are crucial in regulating cell survival, apoptosis and proliferation. Studying
their crosstalk will lay groundwork for clinical trials of Notch targeting therapeutic agents.

CHAPTER II
REVIEW OF RELATED LITERATURE

A. Overview of cervical cancer and breast cancer

1. Overview of cervical cancer

1.1 Introduction to cervical cancer

Cervical and breast cancer are most common cancers that severely endanger
women’s health. Cervical cancer is the second most frequently diagnosed neoplasm in
women worldwide, constituting ~12% of all female cancers and causing ~250,000 deaths
annually. Incidences are higher in developing countries compared to developed countries
(Sankaranarayanan et al., 2006).
Persistent human papillomavirus (HPV) infections are now recognized as the
major cause of cervical cancer. HPV can be referred to as “low-risk” and “high–risk”.
Low risk HPVs include: types 6, 11, 40, 42, 43, 44, 54, 61, 70, 72, 81, and CP6108. They
rarely cause lesions that develop into cancer. High risk HPVs include types 16, 18, 31,
33, 35, 39, 45, 51, 52, 56, 58, 59, 66, 68, and 73. High risk HPVs are more likely to lead
to the development of cancer. HPV types 16 and 18 together cause about 70% of cervical
13
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cancers (Munoz et al., 2003). The vaccine effective against these two HPVs has been
licensed in the U.S. and the EU.
Cervical cancer is considered as a sexually transmitted disease. Women who have
many sexual partners (or who have sex with men or women who had many other
partners) have a greater risk (Marrazzo et al., 2001). Use of condoms reduces, but does
not always prevent transmission.

1.2 Cervical cancer stage and treatment

Cervical cancer evolves from morphologically distinctive non-malignant stages.
Those stages can be classified in three-tier: cervical intraepithelial neoplasia (CIN) and
two-tier systems: squamous intraepithelial lesion (SIL). Mild dysplasia as CIN1
corresponds to Low-grade Squamous Intraepithelial Lesion (LSIL). High-grade
Squamous Intraepithelial Lesion (HSIL) includes moderate dysplasia CIN2 and severe
dysplasia CIN3 (Chivukula et al., 2007).
Cervical cancer is treated by surgery in early stages and chemotherapy and
radiotherapy in advanced stages of the disease. Cervical cancer was once the leading
cause of death for women in the United States. However, during the past few decades,
largely due to widespread use of the Papanicolaou test, incidence and mortality from
cervical cancer have declined significantly. New approaches such as liquid-base
cytology, automated slide analysis, physical parameters and visual inspection using acetic
acid have been developed to improve the accuracy of a cervical screening test.
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1.3 Biomarkers for cervical cancer

Understanding of the molecular signaling pathways in cervical neoplasia
transformation provides the foundation for developing more specific and more accurate
screening biomarkers. Those biomarkers include HPV E6, 7 proteins and cyclin E,
protein required for cell cycle progression, minichromosome maintenance proteins
(MCMs), proliferating cell nuclear antigen (PCNA), P16 and P21 (Martin et al., 2009).
Notch-1 was shown to cooperate with HPV oncoproteins in transforming immortalized
human keratinocytes (Ramdass et al., 2006; Rangarajan et al., 2001). Studying Notch-1
pro-survival signaling pathway could facilitate identification of a new biomarker for
cervical cancer screening and prognosis. Thus, in this thesis, we will focus on elucidating
the mechanism whereby Notch-1 promotes cell survival in cervical cancer.

2. Overview of breast cancer

2.1 Introduction to breast cancer and breast cancer treatment

According to the WHO, breast cancer has become the leading cause of cancer
related mortality in women globally. About 1.3 million women will be diagnosed with
breast cancer annually worldwide and about 465,000 will die from the disease. One out
of eight women develops invasive breast cancer in the U.S.
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Breast cancer is usually first treated by surgery. Based on the tumor size and
cancer stage, lumpectomy or mastectomy including removal and examination of axillary
lymph nodes are performed. In some cases, neo-adjuvant therapy (treatment before the
surgery) may be administered to reduce tumor size before surgery. Breast cancers are also
treated by radiotherapy, chemotherapy and hormone therapy after surgery to reduce
recurrence and relieve pain.

2.2 ER positive versus ER negative breast cancer

Breast cancers can be classified into two groups: Estrogen Receptor positive
(ER+) breast cancer, making up 70% of all breast cancers, or Estrogen Receptor negative
(ER-) ones, constituting the remaining. Estrogen induces tumor cell growth through
binding to ER and initiating hormone responsive gene expressions. The estrogen
downstream proteins presumably promote mammary epithelial cell proliferation (Jordan,
1995). Consequently estrogen has become an obvious therapeutic target giving rise to the
development of selective estrogen receptor modulators (SERMs) such as tamoxifen,
raloxifene; aromatase inhibitors; and estradiol analogs like fulvestrant (Chakrabarti et al.,
2004). However, since these hormone therapies target ER or estrogen, they are not
effective agianst ER- breast cancer. Breast cancers usually progress from benign, ER+,
estrogen dependent, noninvasive tumors to malignant, ER-, estrogen independent,
invasive and metastatic ones. ER- breast cancers are therefore clinically more aggressive
and more difficult for prognosis than ER+ breast tumors (Clarke et al., 1990). This is
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why ER- breast cancer requires more dedicated research to improve the outlook and
treatment. We will study ER- breast cancer in this thesis.

2.3 Biomarkers for breast cancer

Besides ER, other genetic factors also have great impact on the choice of
treatment and prognosis for breast cancer. These genetic biomarkers include: Her2/neu,
BRCA, NF-κB, Notch-1 and Jagged-1. Her2 is the second member of the epidermal
growth factor family (EGFR). Her2 is one of the most important oncogenes in invasive
breast cancer. In about one of every three breast cancers, Her2 is amplified due to a gene
mutation. Her2-positive breast cancers tend to be more aggressive than other types of
breast cancer. They are also less responsive to hormone treatment and chemotherapy
(Lipton et al., 2002). However, Herceptin, a monoclonal antibody against Her2, was
developed and approved by FDA. It was shown to be very effective in killing these
cancer cells and decreases the risk of recurrence. When combined with chemotherapy,
Herceptin increased median survival time by about 25% compared to chemotherapy
alone (Baselga, 2001). Herceptin is one of the drugs designed based on molecular
therapeutic target. It has excellent clinical outcomes and moderate side effects. Herceptin
is a huge success of molecular oriented biomedical research.
In addition to HER2, BRCA1 and BRCA2 are two very important genes
associated with breast cancer, especially in hereditary breast cancer. The names BRCA1
and BRCA2 stand for breast cancer susceptibility gene 1 and breast cancer susceptibility
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gene 2, respectively. They are tumor suppressors, whose function is to repair damaged
DNA and maintain genomic integrity. More than 1,000 mutations in the BRCA1 and
more than 800 mutations in the BRCA2 gene were found. Those mutations cause
production of nonfunctional proteins. A woman’s lifetime risk of developing breast
and/or ovarian cancer is greatly increased if she inherits a harmful mutation in BRCA1 or
BRCA2 (Satagopan et al., 2001). Currently, women with BRCA1 mutations account for
5% of all breast cancer cases.
Genetic tests are available to check for BRCA1 and BRCA2 mutations. This
facilitates the prevention, early detection and management of breast cancer for women
with BRCA1 and BRCA2 mutations. Several options such as surveillance, prophylactic
surgery, risk avoidance and chemoprevention, are available for managing cancer risk in
individuals who have a harmful BRCA1 or BRCA2 mutation ((Bouchard et al., 2004).
NF-κB is another factor that might contribute to tumorigenesis in breast cancer.
NF-κB is a family of transcription factors with a critical role in regulating inflammation,
cell survival, cell differentiation, and cell proliferation. We will discuss the detail of NFκB activation in breast cancer in later section.
Notch-1 and its ligands overexpression have been shown to be poor prognosis
markers for breast cancer. Again, we will talk in detail about Notch-1 signaling in breast
cancer.
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B. Overview of Notch signaling pathway

1. Notch structure

Figure2.1: Notch-1 structure
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Figure 2.1 Notch-1 structure. Notch receptors contain an extracellular subunit NEC and a
transmembrane subunit NTM. The extracellular subunit contains EGF-like repeats associated with
ligand binding and three cysteine-rich Notch/LIN12 repeats (LIN). The transmembrane subunit
contains two protein-protein interaction domains, the RAM domain(R, membrane-proximal RBP-Jassociated molecule domain) and six ankyrin (ANK) repeats. RAM domain interacts with its
transcriptional activator RBP-Jк/CBF-1 and ANK repeats interacts with a different transcriptional
factor MAML1. The transmembrane subunit also contains two nuclear localization signals (NLS)
which flank ANK, a transactivation domain (TAD) and a PEST sequence (P, proline-, glutamate-,
serine- and threonine-rich) which is important for mediating Notch degradation. Similar to the Notch
receptor, Notch ligand has an extracellular domain composed of EGF-like repeats. They have a short
intracellular portion with no recognizable domain structure.

Notch is a single-pass transmembrane receptor that participates in communication
between adjacent cells (Nickoloff et al., 2002; Miele, 2006; Miele et al., 2006). The name
for Notch originated because a partial loss of Notch function causes small notches in
Drosophila wings. Notch signaling, conserved throughout evolution, plays a key role in
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modulating cell fate decisions, cell proliferation, and cell death during development and
postnatal life (Callahan and Raafat, 2001).
There are four Notch receptors (1 to 4) in the mammalian family (Blaumueller
and Artavanis-Tsakonas, 1997), and five ligands: Jagged-1, Jagged-2, Delta-like-1,-3 and
-4 (DLL1, DLL3 and DLL4) (Dunwoodie et al., 1997; Lindsell et al., 1995; Shawber et
al., 1996). The structure and processing of Notch has been well characterized since the
groups of Artavanis-Tsakonas and Young cloned the Notch gene in 1985 (Wharton et al.,
1985). All Notch receptors contain an extracellular subunit NEC and a transmembrane
subunit NTM (Rand et al., 2000). The extracellular subunit contains EGF-like repeats
associated with ligand binding and three cysteine-rich Notch/LIN12 repeats (LIN) that
prevent ligand-independent signaling. The transmembrane subunit contains two proteinprotein interaction domains, the RAM domain(R, membrane-proximal RBP-J-associated
molecule domain) and six ankyrin (ANK) repeats. RAM domain interacts with its
transcriptional activator RBP-J-к/CBF-1 (Tamura et al., 1995) and ANK repeats interacts
with a different transcriptional factor MAML1 (Mastermind-like1). The transmembrane
domain also contains two nuclear localization signals (NLS) which flank ANK, a
transactivation domain (TAD) and a PEST sequence (P, proline-, glutamate-, serine- and
threonine-rich) which is important for mediating Notch degradation (Rechsteiner, 1988).
Notch-1 stucture is illustrated in Figure 2.1. Similar to the Notch receptor, Notch ligand
has an extracellular domain composed of EGF-like repeats, which facilitate interactions
with the Notch family. They also contain an amino-terminal structure called DSL (an
acronym for Delta, Serrate and LAG-2) which is necessary for interaction with Notch
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receptors (Rebay et al., 1991). They have a short intracellular portion with no
recognizable domain structure.

2. Notch processing

As shown in Figure 2.2, Notch proteins are derived from large polypeptide
precursors. The precursor undergoes several enzymatic cleavage events while becoming
a mature protein. The first proteolytic cleavage known as S1 is mediated by a furin-like
protease (Logeat et al., 1998). This cleavage produces two fragments: one 180 kDa
fragment that consists of the extracellular subunit of the protein (NEC) and a 120 kDa,
membrane-tethered, intracellular portion containing only a short extracellular piece
known as NTM. NEC and NTM are non-covalently associated on the cell surface until
activation by a ligand (Rand et al., 2000). A specific ligand activates Notch signaling via
binding to EGF repeats of Notch receptor from a neighboring cell, triggering the
dissociating the NEC from NTM. The conformational change resulting from ligandreceptor interaction renders the extracellular stump of NTM susceptible to the S2 cleavage
by TACE (TNF-alpha converting enzyme), a member of a disintegrin and
metallaprotease (ADAM) family (Brou et al., 2000). This cleavage event triggers
presenilin, a catalytic subunit of a gamma-secretase complex, to conduct the S3 cleavage
within the transmembrane sequence, releasing an intracellular domain of Notch, NIC
(Saxena et al., 2001). NIC is considered the active form of Notch. Inhibiting gammasecretase activity prevents the final cleavage of the Notch receptor, blocking Notch signal
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transduction (Shi and Harris, 2006). After it is released from the plasma membrane, NIC
is translocated into the nucleus where it modulates gene expression primarily, but not
exclusively, by binding to a ubiquitous transcription factor CBF-1 (Artavanis-Tsakonas et
al., 1999).

Notch can be also activated without a ligand, since the noncovalent

interaction between NEC from NTM is completely dependent on the Ca2+-binding LIN
repeats located in NEC. Calcium chelators such as EDTA or mutation of the LIN repeats
can deplete the interaction (Rand et al., 2000) and activate the Notch pathway without
ligand stimulation.
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Figure 2.2 Notch-1 processing: Notch proteins are derived from large polypeptide
precursors. The precursor undergoes several enzymatic cleavage events while becoming a
mature protein. The first proteolytic cleavage known as S1 is mediated by a furin-like
protease. This cleavage produces two fragments: one 180 kDa fragment that consists of the
extracellular subunit of the protein (NEC) and a 120 kDa, membrane-tethered, intracellular
portion containing only a short extracellular piece known as NTM. The conformational change
resulting from ligand-receptor interaction renders the extracellular stump of NTM susceptible
to the S2 cleavage by TACE (TNF-alpha converting enzyme), a member of a disintegrin and
metallaprotease (ADAM) family. This cleavage event triggers presenilin, a catalytic subunit
of a gamma-secretase complex, to enact the S3 cleavage within the transmembrane sequence,
releasing an intracellular domain of Notch, NIC. NIC is considered the active form of Notch.
Inhibiting gamma-secretase activity prevents the final cleavage of the Notch receptor,
blocking Notch signal transduction.
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3. Canonical Notch signaling

After it is released from the plasma membrane, NIC is translocated into the
nucleus where it modulates gene expression primarily, but not exclusively, by binding to
a ubiquitous transcription factor CBF-1 (Artavanis-Tsakonas et al., 1999). CBF-1 acts as
a constitutive repressor at the promoter by recruiting co-repressors including SMRT
(silencing mediator for retinoid and thyroid receptor), N-coR (nuclear receptor corepressor), SKIP (Ski interacting protein), CIR (CSL-interacting repressor) and HDAC-1
(histone deacetylases-1) (Hsieh et al., 1999; Kao et al., 1998). The active NIC is thought
to be initially recruited to the CBF-1: DNA complex by the RAM sequence of NIC,
which has high affinity for the β-trefoil domain of CBF-1 (Lubman et al., 2007; Nam et
al., 2006). The ANK domain of NIC further stabilizes DNA:CBF:NIC complex through
the Rel-homology portion of CBF-1 to create a high affinity binding site for Mastermindlike 1 (MAML-1) (Nam et al., 2006, Wilson et al., 2006). Sequentially, MAML-1
recruits histone acetyltransferases, such as p300, which promote assembly of initiation
and elongation complexes which, together with PCAF (p300 associated factor), cooperate
to enhance transcriptional activation in the presence of p300 in vitro (Oswald et al., 2001;
Wallberg et al., 2002). The net result of the Notch activation is converting CBF-1 from a
constitutive repressor to a transcriptional activator by displacing the co-repressors and
recruiting a co-activator complex.
The target genes of Notch include hairy enhancer of split genes (HES) and HESrelated repressor protein (HERP) (Iso et al., 2003), HEY family (Maier and Gessler,
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2000), which are helix-loop-helix transcriptional regulators modulating differentiation,
cell cycle mediator p21 (Rangarajan et al., 2001), and cyclin D (Ronchini and
Capobianco, 2001) as well as NF-κB family (Cheng et al., 2001) and PPAR family
(Garces et al., 1997; Nickoloff et al., 2002) transcription factors. Since many Notch
targets are themselves transcription factors, Notch activation can result in complex
changes in gene expression profiles, potentially involving hundreds of genes. However,
the consequences of Notch activation and the downstream genes that it affects are
dependent on the cellular context in which they occur.
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Figure 2.3 Canonical Notch signaling. After it is released from the plasma membrane, intracellular
Notch NIC is translocated into the nucleus where it modulates gene expression by binding to a
ubiquitous transcription factor CBF-1. CBF-1 acts as a constitutive repressor at the promoter by
recruiting co-repressors including silencing mediator of retinoid and thyroid hormone receptors
(SMRT), N-coR, and histone deacetylases. Nuclear Notch displaces the co-repressors and recruits a
co-activator complex, that includes histone acetyl tansferases PCAF, GCN5 or p300, and
mastermindlike 1 (MAML1). The target genes of Notch include hairy enhancer of split genes (HES)
and HES-related repressor protein (HERP), HEY family, cyclin D,c-Myc, as well as NF- B
family and PPAR family transcription factors.
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4. Non-canonical Notch signaling

The CBF-1-dependent signaling pathway does not mediate all functions of Notch;
mounting evidence points to the existence of CBF-1-independent Notch signaling
pathways. One of these pathways involves the protein Deltex and possibly c-Jun Nterminal kinase (JNK, a member of the MAP kinase family) (Ramain et al., 2001;
Zecchini et al., 1999). Deltex is an evolutionarily conserved cytoplasmic, zinc-finger
protein which binds to the ankyrin repeats of Notch (Matsuno et al., 1998). This deltex
and Notch complex does not enter the nucleus, but appears to inhibit JNK activity by
decreasing its phosphorylation (Jang et al., 2004). The reduced JNK activity results in
downregulation the phosphorylation of the E47 transcription factor (Ordentlich et al.,
1998), which is important in transcription activation of B-cell specific immunoglobulin
genes.
Recent evidence also suggests another cytoplasmic pathway of Notch signaling.
Specifically, Notch has been shown to activate the PI3-kinase (PI3K)-Akt pathway in a
variety of cells (Rangarajan et al., 2001; Nair et al., 2003). In T-cells, this is reported
that Notch1IC forms a cytoplasmic complex with PI3K, and the non-receptor protein
tyrosine kinase p56Lck, a Src-related enzyme (Sade et al., 2004). The complex appears to
be membrane associated, but activates Akt, presumably through formation of a PIP3
intermediate. These observations suggest that Notch can act as a scaffold for kinase
activation cascades independently of its nuclear effects.
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In addition, there are several studies talking about Notch regulation on NF-κB
activity without involvement of CBF-1. We will discuss these in detail in the section of
Notch and NF-κB.

C. Notch-1 in cervical and breast cancer

1. Notch-1 in cervical cancer

Deregulated expression of Notch receptors, ligands and targets was observed in
numerous solid tumors including cervical, head and neck, endometrial, renal, lung,
pancreatic, ovarian, breast and prostate carcinomas, osteosarcoma, mesothelioma,
gliomas, and medulloblastomas (Miele et al., 2006). In cervical cancer, increased
expression of Notch-1 and Notch ligands was reported (Daniel et al., 1997; Gray et al.,
1999; Zagouras et al., 1995). Low level of Notch-1 was expressed in normal cervical
epithelium and higher level was detected in the membrane and cytoplasm of cells of
precancerous cervical lesions. Accumulation of Notch-1 and its ligand Jagged-1 and
downregulation of Manic Fringe, a negative regulator of Notch signaling coincided with
the progression of high-grade precursor lesions to invasive cervical cancers
(Veeraraghavalu et al., 2004). High level of Notch-1 was found in the nucleus in cervical
cancer, indicating that Notch-1 was in cleaved and active form. More importantly, Notch1 was shown to cooperate with HPV oncoproteins in transforming immortalized human
keratinocytes (Ramdass et al., 2006; Rangarajan et al., 2001). These cells transfected
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with E6, E7 and Notch-1 were able to generate xenograft tumors in nude mice
(Chakrabarti et al., 2004) . These observations were also extended to primary human
keratinocytes (Lathion et al., 2003). Notch-1 levels and CBF-1 transcriptional activity
were increased by HPV16 oncoproteins E6 and E7 in primary mouse embryo cells
(Weijzen et al., 2003). Inhibiting Notch signaling by antisense silencing in CaSki cervical
cancer cells abolished proliferation and anchorage-independent growth in vitro (Weijzen
et al., 2002) and completely blocked the growth of CaSki xenografts in vivo (Weijzen et
al., 2003). Collectively, these data have suggested a pivotal role of dysregulated Notch in
transforming epithelial cells.
However, there was some controversy raised by Talora et al. They found that
invasive and metastatic cervical cancers as well as cell lines derived from cervical cancer
did not express Notch-1. Activated Notch signaling leads to growth arrest of cervical
cancer derived cell lines (Talora et al., 2005; Wang et al., 2007).
It is difficult to compare data obtained with different antibodies by different
groups, and immunohistochemistry is hardly quantitative. However，in a later study on a
large quantity of clinical samples, Notch-1, its ligand Jagged-1 and its downstream
targets were observed and were accompanied by activation of the NF-κB pathway
(Ramdass et al., 2006). Moreover, Lathion et al showed that the effects of Notch-1 in
cervical keratinocytes are strikingly dose-dependent: high levels of constitutively active
Notch-1 suppress E6 and E7 as found by Talora et al, but moderate levels of Notch-1
promote keratinocyte transformation by E6 and E7.

30
The data from our lab also indicate that Notch-1 protein is present in most
cervical carcinomas, in agreement with Ramdass et al. (Ramdass et al., 2006) and in
cervical carcinoma lines, in agreement with Lathion et al. (Lathion et al., 2003). Notch-2
and 4 appear to be co-expressed with Notch-1. The pattern of Notch-1 expression appears
to change from granular and membrane-associated in normal cells to diffuse and
primarily cytoplasmic in cancer cells (Song et al., 2008). This may be responsible for
apparent differences in published reports.

2. Notch-1 in breast cancer

2.1 Notch-1 expression in breast cancer

Notch-1 has been shown to be oncogenic not only in cervical cancer but also in
breast cancer. Aberrant activation of Notch signaling was observed in a large number of
human breast carcinomas. In Weijzen’s research, all seven human primary breast ductal
carcinomas studied were positive for Notch-1, whereas normal breast ducts and lobules at
the margins of the tumor sections exhibited little or no detectable Notch-1 staining
(Weijzen et al., 2002). In another study, the accumulation of intracellular Notch and
elevated Notch signaling were observed in a variety of human breast carcinomas (Reedijk
et al., 2005; Stylianou et al., 2006). Our lab confirmed that Notch expression was
deregulated in human breast cancer as opposed to normal breast cells. Ductal and lobular
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carcinomas consistently expressed high levels of Notch-1 and Notch-4 as compared to
normal breast tissue, which expressed Notch-1 at barely detectable levels.
Parr C et al showed that there were aberrant levels of Notch-1 and Notch-2 in
breast cancer tissues compared with normal breast tissue by qualitative and quantitative
RT-PCR analysis along with immunohistochemical staining. These authors suggested
that a high level of Notch-1 may be associated with a poorer outlook for the breast cancer
patient, while a high level of Notch-2 correlated to a higher chance of survival (Parr et
al., 2004).
Numb, a negative regulator of Notch signaling, was lost in > 50% of human
mammary carcinomas due to specific Numb ubiquitination and proteasomal degradation
and its lower levels were found to be associated with grade and proliferation rate (Pece et
al., 2004). In later study, Numb was shown to form a complex with p53 and the E3
ubiquitin ligase MDM2. This interaction resulted in prevention of ubiquitination and
degradation of p53. Thus, Numb loss in breast cancer led to decreased p53 levels and
increased chemoresistance (Colaluca et al., 2008).
Our lab showed that Notch-1 activity was aberrantly elevated in Herceptin
resistant breast cancer cells compared to Herceptin sensitive cells. Her2 inhibition
activated Notch-1 signaling which confered cells resistance to Herceptin (Osipo et al.,
2008).
The expression levels of Notch-1 and Jagged-1 have been shown to be prognostic
markers for breast cancer patient survival. Reedijk et al showed that high-level
expression of Notch-1 or Jagged-1 predicted poor overall survival in breast cancer
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patients, combined higher levels of both indicated even worse outlook. The same group
also showed high level Jagged-1 mRNA and protein predicted poor outcome in breast
cancer and that Jagged-1 expression was positively associated with recurrence in lymph
node-negative breast cancer (Reedijk et al., 2005; Reedijk et al., 2008; Dickson et al.,
2007).

2.2 ER- breast cancer has highest Notch-1 activity

Reedijk group also observed that high levels of Notch-1 and Jagged-1 were
mostly found in the ER- basal phenotype breast cancer (ER-, PR-, Her2-), which is the
most aggressive tumor. This parallels with our lab finding that Notch activity negatively
correlates with ER status. Specifically, Notch-1 activity was highest in ER-, Her2- cells
(Rizzo et al., 2008). That was one of the reasons we chose MDA-MB-231 cells which
are ER-, Her2- as our model to study the Notch-1 signaling.
Overall, the data support the idea that Notch plays an oncogenic role in human
breast cancer.

2.3 Notch inhibition in breast cancer

Inhibition of Notch by pharmacological agents and molecular means has been
shown to suppress breast cancer growth. Pharmacological inhibition of Notch suppressed
Numb negative breast tumors growth (Pece et al., 2004). Attentuation of Notch signaling
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by overexpressing Numb reverts the transformed phenotype of human breast cancer cell
lines, including the ER- breast cancer cell line MDA-MB-231 (Stylianou et al., 2006).
Blocking Notch by siRNA resulted in reduced proliferation by 80% and reduced
anchorage-independent growth. Inhibition of ligand-mediated Notch signaling in
xenografted Slug-positive/E-cadherin-negative breast cancers promoted apoptosis and
inhibited tumor growth and metastasis (Leong et al., 2007).
Our lab also showed that in MDA-MB-231 cells, either Notch-1 knockdown or
GSI decreased cyclin A and B1; caused G2 arrest, p53-independent induction of NOXA,
and death. In T47D:A18 cells, the same targets were affected, and Notch inhibition
potentiated the effects of tamoxifen. In vivo, GSI arrested the growth of MDA-MB-231
tumors. In combination with tamoxifen，GSI caused regression of T47D:A18 tumors
(Rizzo et al., 2008). Moreover, we found that Notch-1 siRNA or GSI resensitized
Herceptin-resistant BT747 cells to Herceptin (Osipo et al., 2008). All these findings
suggest that Notch signaling is a potential therapeutic target in breast cancer.
A number of Notch inhibitors have been developed, such as antisense, siRNA,
overexpressed Numb or deltex, monoclonal antibodies, soluble ligands, soluble decoys to
EGFR 11 and 12, inhibitors of enzyme involved in glycosylation and pharmacological
inhibitors of gamma-secretase. Gamma-secretase inhibitors (GSIs) have broad antineoplastic

activity

and

immediate

therapeutic

potential.

GSI

has

superior

pharmacological properties compared to antibodies and siRNA and relatively cheaper.
Several GSIs are developed in cooperation with research into drugs for Alzheimer’s
disease. GSI is currently in phase III clinical trials. However, like virtually all small-
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molecule agents, they also have non-specific effects since GSI target all Notch receptors
and other substrates such as amyloid precursor protein. Given that Notch is a critical
transcription regulator in many physiological events, inhibiting Notch might have
widespread off target effects. Development of more specific inhibitor and identification
of proper therapeutic doses and administration frequency are needed for more effective
cancer therapy. In my experiments in the thesis, I used GSI as well as siRNA to
complement each other.

2.4 Potential mechanism of Notch oncogenic function

The oncogenic role of Notch is implicated in cervical and breast cancer, however,
the mechanism of its transforming function is not well understood. Most studies have
focused on the ability of Notch to collaborate with other proteins to transform normal
cells. Collaborating oncoproteins that have been identified include: adenovirus E1A
(Capobianco et al., 1997), HPV E6 and E7 (Rangarajan et al., 2001), Ras (Fitzgerald et
al., 2000), Myc (Girard et al., 1996), and SV40 large T antigen (Bocchetta et al., 2003).
Notch, together with collaborative proteins, transform cells by promoting cell
proliferation and survival, inhibiting differentiation, suppressing apoptosis.
Potentially oncogenic targets of Notch-1 include cyclin D1 and D3, cyclin A,
SKP2 (S-phase kinase-associated protein 2), PI3K (phophatidylinositol 3-kinase), Akt,
Her2, NF-κB (nuclear factor-κB ), β-catenin, signal transducers and activators of
transcription-3, and hypoxia-inducible factor-1α (Miele et al., 2006). Here, in this thesis,
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we investigated one of the downstream targets of Notch-1: NF-κB. NF-κB is a prosurvival signal in cervical and ER- breast cancer. We hypothesized that Notch-1
promotes cell survival by activating NF-κB activity.

D. Introduction to NF-κB

1. NF-κB members and activation

Nuclear Factor-kappa B (NF-κB), is a family of transcription factors with a
critical role in regulating inflammation, cell survival, cell differentiation, and cell
proliferation. In mammals, there are five members of the NF-κB family, including RELA
(p65), RELB, c-REL, NF-κB1 (p105/p50), and NF-κB (p100/p52), which associate with
each other to form different homodimers and heterodimers to regulate the expression of
their downstream targets (Karin and Greten, 2005; Luo et al., 2005).
All family members are characterized by the presence of a Rel homology domain
(RHD) which contains a nuclear localization sequence (NLS) and is involved in
sequence-specific DNA binding, dimerization and interaction with the inhibitory IκB
proteins. Members of the NF-κB family can be divided into two classes: one containing
C-terminal transcriptional activation domains RelA/p65, RelB, and c-Rel, and the other
which lacks the activation domains p50/p105 (NF-κB1) and p52/ p100 (NF-κB2). A
homodimer or heterodimer can potently transactivate NF-κB dependent promoters if it
contains RelA/p65, RelB, or c-Rel, whereas p50 homodimer and p52 homodimer act as
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repressors for gene transcription because of the absence of the activation domain (Hayden
and Ghosh, 2004; Baeuerle and Baltimore, 1996).
There are two most frequently studied NF-κB pathways: the canonical (classic)
and noncanonical (alternative). The canonical pathway of NF-κB activation is mediated
by rapid phosphorylation of IκB α by the IKK complex. Take the predominant form of
NF-κB, heterodimer of p65 and p50, for example. It is inactive in the cytoplasm as a
result of binding to inhibitory proteins of the IκB family (IκBs). In mammalian cells,
there are three principal IκBs, IκBα, IκBβ and IκBε, which function in part by using a
core domain composed of six to seven ankyrin repeats to bind to the RHD and thereby
masking the NLS (Perkins, 2007).
In response to numerous stimuli, such as cytokines, chemokines, mitogens, and
bacterial and viral infections, an IKB kinase (IKK) complex is activated by IKK kinases
(Karin, 1999). Activated IKK complex consisting of two catalytic subunits (IKKα and
IKKβ) and an IKKγ regulatory subunit phosphorylates IκBs at the two conserved serine
residues in the N-terminal domain, leading to 26s proteasome mediated degradation of
IκB. Degradation of IκB releases NF-κB, enabling it to translocate to the nucleus and
rapidly induce a variety of genes encoding matrix metalloproteinases, inflammatory and
chemotactic cytokines, and antiapoptotic proteins (Karin et al., 2002; Karin and Lin,
2002; Li and Verma, 2002) as shown in Figure 2.4.
In contrast, the noncanonical pathway involves the upsteam kinase NF-κBinducing kinase (NIK), which activates IKKα homodimers instead of IKK complex in
response to certain members of the TNF family. This pathway is mediated by
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phosphorylation of p100 and subsequent processes to p52 through ubiquitin-depedent
processing. The consequence of activation of the noncanonical pathway is p52/RelB
heterodimer, which has a higher affinity for distinct κB elements and might therefore
regulate a distinct subset of NF-κB targets (Karin and Greten, 2005; Luo et al., 2005).
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Figure 2.4 Canonical NF-κB Signaling Pathway
Stimulation
Iκ B

Transcriptional
Factors
-------------------RelA/p65
p50
p52
cRel
RelB

IKKIKK-γ
IKKIKK-α IKKIKK-β

p50 p65
p

p

Iκ B
p50 p65

p

p

Iκ B
Proteasome-mediated
degradation

p50 p65

p50 p65

Figure 2.4 Canonical NF-кB signaling pathway. In response to numerous stimuli, such as cytokines,
chemokines, mitogens, and bacterial and viral infection, an IκB kinase (IKK) complex is activated by IKK
kinases. Activated IKK complex consisting of two catalytic subunits (IKKα and IKKβ) and an IKKγ
regulatory subunit phosphorylates IκBs at the two conserved serine residues in the N-terminal domain,
leading to 26s proteasome mediated degradation of IκB. Degradation of IκB releases NF-кB enabling it to
translocate to the nucleus and rapidly induce a variety of genes encoding matrix metalloproteinases,
inflammatory and chemotactic cytokines, and antiapoptotic proteins.

，
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Generally speaking, NF-κB is considered as an oncogene in cancer. NF-κB
contributes to oncogenesis by stimulating cell proliferation, inhibiting apoptosis,
increasing metastasis and angiogenesis. The anti-apoptotic activity of NF-κB depends on
gene induction. In fact, NF-κB induces the expression of a number of genes whose
products can inhibit apoptosis; these include cellular inhibitors of apoptosis (c-IAPs),
caspase-8-c-FLIP (FLICE inhibitory protein), A1, TNFR-associated factor 1(TRAF1) and
TRAF2. These anti-apoptotic proteins work in a coordinated manner to block apoptosis at
multiple steps along the apoptotic signaling cascade. Although the majority of evidence
provides overwhelmingly strong support to the anti-apoptotic function of NF-κB, there
are few sporadic reports that NF-κB may contribute to induction of pro-apoptotic
molecules. They include DR6 (death receptor 6) (Kasof et al., 2001), DR4, DR5 (Ravi et
al., 2001) and Fas (Zheng et al., 2003). However, whenever the genes encoding death
receptors are induced, so are the anti-apoptotic molecules that neutralize their proapoptotic activity. Thus, little physiological evidence exist for a pro-apoptotic function of
NF-κB.

2. IKKα

Despite the fact that IKKα and IKKβ are very similar in structure, they have
different roles in the NF-κB pathway and different NF-κB-independent functions. IKKβ
appears to predominantly contribute to IκB α phosphorylation, while IKKα has more
physiological functions than inducing IκB degradation and releasing of NF-κB.
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IKKα is able to phosphorylate a number of substrates.

For example, it

phosphrylates p100 and leads to proteasome-dependent processing of p100 to p52
(Perkins, 2007). It also phosphorylates RelA at Ser 536 in macrophages and stimulates its
degradation and thus promotes resolution of inflammation (Lawrence et al., 2005). In
addition to phosphorylating components of the NF-κB and IKK pathways, IKKα
regulates gene expression by modulating chromatin structure and facilitating recruitment
of co-activators. The nuclear function of IKKα include the phosphorylation and
activation of the estrogen receptor α, together with its co-activator protein SRC3 (steroid
receptor coactivator 3) in breast cancer cells (Park et al., 2005) and phosphorylation and
stabilization of the β-catenin oncoprotein (Albanese et al., 2003; Carayol and Wang,
2006) on cyclin D1 promoter. IKKα also phosphorylates H3 Ser10 through association
with cyclic-AMP responsive element binding (CREB)-binding protein (CBP) (Anest et
al., 2003; Yamamoto et al., 2003). Moreover, IKKα phosphorylates SMRT co-repressor
and thus resulting in release of HDAC and facilitation of NF-κB subunits recruitment on
NF-κB dependent gene promoters (Hoberg et al., 2004). This phosphorylation leads to
de-repression of gene transcription. The same phenomenon is also detected on Notchdependent promoters (Aguilera et al., 2004; Fernandez-Majada et al., 2007), indicating
IKKα kinase function independent of classical NF-κB activation. In our lab, we found
that IKKα is recruited to the promoters of NF-κB dependent gene c-IAP2 and IκB α in
CaSki cells, presumably phosphorylating SMRT and derepressing gene transcription. The
recruitment of IKKα on c-IAP2 and IκB α promoters is Notch-1 dependent, suggesting
the crosstalk between NF-κB and Notch-1.
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IKKα also has kinase-independent roles in the regulation of keratinocyte
differentiation (Hu et al., 2001). Taken together, it can be concluded that IKKα activation
may result in more widespread effects on cell signaling than previously realized.

3. NF-κB in cervical cancer

Recent immunohistochemistry data on a large series of 352 patients (Ramdass et
al., 2006) indicate that activation of Notch signaling is observed in the majority of
cervical cancers. The activation of Notch signaling is accompanied by activation of the
NF-κB pathway. The Notch signaling is determined by expression levels of intracellular
Notch-1, Hes1, CDK9 (cyclin-dependent kinase 9) and Jagged-1. The NF-κB activity is
determined by nuclear staining for p50 and p65 and expression of NF-κB target genes.
NF-κB is a major survival pathway that is highly relevant to cervical cancer. Previous
studies have shown that NF-κB is constitutively activated in human cervical squamous
cell carcinomas as compared to normal cervical epithelium. Constitutive activation of
NF-κB with nuclear accumulation of p50 and p65 with cervical cancer progression has
been described in clinical specimens (Prusty et al., 2005; Nair et al., 2003). The positive
rates of NF-κB and BCL-2 based on immunohistochemistry were significantly higher in
cervical cancer than in normal cervical tissue (Xia et al., 2005).
Blocking NF-κB in cervical cancer cells may not only help eradicate tumor cells
but also increase sensitivity to other conventional therapies. The cytotoxicity of arseninc
trioxide (Wei et al., 2005; Woo et al., 2004), celecoxib (Kim et al., 2004) and curcumin
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and its analog (Divya and Pillai, 2006; Kasinski et al., 2008) on cervical cancer cells is
mediated in part by NF-κB inhibition. Inhibition of NF-κB sensitizes cervical cancer
cells to cisplatin induced apoptosis (Venkatraman et al., 2005). Inhibition of NF-κB by
the proteasome inhibitor Velcade enhances radiosensitivity of certain human cervical
carcinoma cancer cells in vitro (Kamer et al., 2009).

4. NF-κB in ER - breast cancer

Several studies suggest that NF-κB is important in breast cancer carcinogenesis
initiation and progression. NF-κB was activated during neoplastic transformation of
mammary epithelial cells such as HMEC and MCF-10A (Kim et al., 2000). Breast
cancers usually progress from a hormone dependent, nonmetastatic, antiestrogensensitive phenotype to a hormone independent, antiestrogen and chemotherapy resistant
phenotype. The latter phenotype is highly invasive and metastatic. This progression is
accompanied by downregulation of ER expression, mutation of ER and altered regulation
of ER responsive genes. NF-κB was found to contribute to breast cancer progression
from ER+ breast cancer to ER- breast cancer. NF-κB was found to be highly active in
ER- breast cancer cell lines as compared to ER + breast cancer cell lines, as well as in
ER- primary breast tumors versus ER+ primary breast tumors. p100 subunit of NF-κB
was overexpressed in a majority of breast cancer samples and breast cancer cell lines.
Constitutive DNA binding of NF-κB and elevated concentration of NF-κB were also
detected in extracts from poorly differentiated ER- primary tumors (Biswas et al., 2000;
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Nakshatri et al., 1997; Bhat-Nakshatri et al., 1998). In addition, the transcription of NFκB regulated genes was increased in breast tumors compared to adjacent normal tissues.
These data imply that dysregulated NF-κB expression is associated with mammary
carcinogenesis, especially in ER- breast cancer cells with more aggressive and metastatic
phenotype.
Constitutive active NF-κB could be correlated with increased levels of members
of epidermal growth factor receptor family EGFR, including Her2 in ER- cells (Biswas et
al., 2000; Biswas et al., 2001; Biswas et al., 2004; Nakshatri et al., 1997) and linked to
elevated expression and activity of IKK (Romieu-Mourez et al., 2001).
Elevated NF-κB activation in ER- breast cancer has also been suggested to be
responsible for chemoresistance and metastatic growth. Chemotherapeutic drugs and γ
irradiation usually caused apoptosis via activation of specific caspases. However, they
also induce the activation of NF-κB. Active anti-apoptotic NF-κB protected the cells
from apoptosis induced by chemotherapy reagent and radiation. This may explain the
chemo-resistance and radiation resistance (reviewed in (Nakshatri et al., 1997)).
NF-κB has been considered a potential therapeutic target for ER- breast cancer
(Biswas et al., 2000; Biswas et al., 2001; Biswas et al., 2004; Nakshatri et al., 1997).
Inhibiting NF-κB activity by different methods, such as microinjection of IKBα;
antibodies against RelA or NF-κB decoys (Sovak et al., 1997); inhibition of PKC;
overexpression of dominant negative IKKβ (Biswas et al., 2001); an IκB α superrepressor; the use of a IKKγ-blocking peptide; application of IKK inhibitor
cyclopentenone (Ciucci et al., 2006); or proteasome inhibitor bortezomib caused cell
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apoptosis or tumor regression in ER- breast cancer in vitro or in vivo. Inhibition of NF-κB
enhanced the sensitivity of tumor cells to apoptosis induced by chemo drugs and
radiation. Therefore, simultaneous use of NF-κB inhibitors and chemotherapy or
radiation might be advantageous.

5. Some important NF-κB dependent genes in cancer

c-IAP2 (cellular inhibitor of apoptosis protein) is a member of inhibitor of
apoptosis proteins (IAPs) family. Members of this family are characterized by the
presence of a variable number of Baculoviral IAP repeat (BIR) motifs. c-IAP2 has three
BIR domains, a RING domain and one CARD (CAspase Recruitment Domain) domain.
c-IAP2 is one of the anti-apoptotic proteins regulated by NF-κB. Recent evidence
indicated that c-IAP2 was frequently overexpressed in cancer and its expression level was
implicated in contributing to tumorigenesis, chemoresistance, disease progression and
poor patient survival (Hunter et al., 2007). It suppresses the apoptosis induced by both
extrinsic and intrinsic pathways through direct inhibition of effecter caspases (caspases3，-6，and 7) (Deveraux et al., 1997; Deveraux et al., 1998). It also promotes cancer
cell survival by functioning as E3 ubiquitin ligases that maintain constitutive
ubiquitination of the RIP1 (Receptor interacting protein 1) adaptor protein (Bertrand et
al., 2008). Inhibition of multiple IAPs increased apoptosis in response to the Her2
antagonists Herceptin, Lapatinib or Gefitinib in Her2-overexpressing breast cancer
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BT474 cells, or Gefitinib in EGFR overexpressing breast cancer MDA-MB-468 cells
(Foster et al., 2009).
A20 is also called “tumor necrosis factor α-induced protein 3 (TNFAIP3)”. Its
expression is mediated through activation of NF-κB. A20 inhibits TNF receptor signaling
by mediating the ubiquitination and proteasomal degradation of RIP1 (Receptor
interacting protein 1) which is essential for TNF-induced NF-κB activation (Vereecke et
al., 2009). Depending on stimulus and cellular context, A20 could be anti-apoptotic or
pro-apoptotic. A20 expression was found to be correlated with the differentiation stages
of nasopharyngeal carcinoma (Codd et al., 1999) and associated with resistance to O6alkylating agents in glioblastoma cells. It was proposed as a predictive marker associated
with patient survival (Bredel et al., 2006). High A20 expression has also been shown to
confer breast cancer cells resistance to apoptosis induced by TNF-α (Opipari, Jr. et al.,
1992). Recently, Vendrell et al (Vendrell et al., 2007) showed that A20 was an E2
regulated gene. Its expression correlated with ER expression in both cell lines and tumor
samples. Overexpression of A20 in ER+ breast cancer cells resulted in resistance to
tamoxifen and hypersensitivity to E2. A20 was highly expressed in tamoxifen resistant
cells and moreover it was overexpressed in more aggressive breast tumors (ER-, PR- and
high histological grade). These data indicated that A20 was responsible for the
development of tamoxifen resistance and associated in vivo with poor prognostic tumor
marker. Thus, A20 was proposed a good marker for tumor aggressiveness in breast
cancer.
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6. TNF-α, apoptosis and cancer

Tumor necrosis factor (TNF) is a multifunctional cytokine with critical role in
regulating cell survival, proliferation, differentiation, and death. TNF was first identified
as an inflammatory cytokine with its ability to suppress tumor cell proliferation and
induce tumor regression (Matthews and Watkins, 1978). While scientists were trying to
utilize TNF as a powerful anticancer treatment, the paradoxical tumor-promoting effect
of TNF became apparent. On one hand, TNF induces apoptosis. On the other hand, TNF
stimulates proliferation, survival, migration, and angiogenesis in most cancer cells that
are resistant to TNF-induced cytotoxicity, resulting in tumor promotion.
TNF receptor 1 (TNFR-1) mainly mediates TNF's cellular signaling in most cell
types. TNFR-1 is a death domain (DD)-containing receptor capable of inducing cell
apoptosis (Wajant et al., 2003). TNFR-1 forms a homotrimer to recruit TNFR-associated
death domain (TRADD) after TNF, a natural homotrimer, binds to the receptors. TRADD
recruits downstream adaptor proteins such as receptor interacting protein (RIP), TNFR
associated factor 2 (TRAF-2), and Fas-associated death domain (FADD) to deliver
signals for distinct signaling pathways. These adaptor proteins further recruit key
molecules that contribute to intracellular signaling to activate NF-κB, mitogen activated
protein kinases (MAPKs), and cell death (Aggarwal, 2003).
It is well established that TNF induces apoptosis in a variety of cell types. TNF
induces apoptosis through extrinsic apoptosis and mitochondria-mediated (intrinsic)
apoptosis pathway. The extrinsic apoptosis pathway is initiated from TNF binding to
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TNFR1, provoking the recruitment of TRADD, RIP, FADD, and caspase-8. Active
caspase-8 then activates the executor capsases-3 and -7, resulting in cell apoptosis. The
mitochondria-mediated (intrinsic) apoptosis pathway is mediated by caspase-8 activating
BCL-2 interacting domain (Bid), a BH3-only Bcl2 family member. Caspase-8 cleaves
Bid to generate tBid, which promotes release of cytochrome c and second mitochondriaderived activator of caspase (Smac) from mitochondria to the cytosol. Cytochrome c
forms a complex with apoptotic protease activating factor 1 (Apaf-1) and pro-caspase-9
to form apoptosome, leading to caspase-9-mediated activation of the executor caspases
(Wang, 2001). Smac binds to and inhibits the inhibitor of apoptosis proteins to accelerate
apoptosis. These proteins include c-IAP1, c-IAP2, X-linked Inhibitor of Apoptosis
Protein (XIAP) and survivin.
However, the tumor-destructive activity of TNF was at its height, came the
growing paradoxical observation that TNF was implicated in contributing to cellular
transformation, survival, proliferation, invasion, angiogenesis, and metastasis. Emerging
reports have shown that the serum TNF concentration is elevated in cancer patients
(Ahmed et al., 2001; Ferrajoli et al., 2002). Moreover, the high TNF expression level in
pre-cancerous and tumor cells is linked with the progression of malignant diseases such
as chronic lymphocytic leukemia, Barrett's adenocarcinoma, prostate cancer, breast
cancer, and cervical carcinoma (Ahmed et al., 2001; Ferrajoli et al., 2002; Tselepis et al.,
2002; Michalaki et al., 2004; Garcia-Tunon et al., 2006). TNF has been shown to
promote tumorigenesis and growth via activating NF-κB (Suzukawa et al., 2002; Hu et
al., 2004) or a PKCα- and AP-1-dependent pathway (Arnott et al., 2002). TNF has also
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been documented to promote tumor angiogenesis in U251 glioma cells (Nabors et al.,
2003), ovarian cancer cells (Kulbe et al., 2007), a mouse lung metastasis model (Tomita
et al., 2004). TNF enhances cancer invasion and metastasis by accelerating the epithelialmesenchymal transition (EMT) (Bates and Mercurio, 2003; Bates et al., 2004; Chuang et
al., 2008), inducing matrix metalloproteases (MMP-2, -3, -9, -12) (Esteve et al., 2002;
Hagemann et al., 2004; Cheng et al., 2007) or α2β1 integrin (Montesano et al., 2005),
activating focal adhesion kinase (FAK), up-regulating of macrophage migration
inhibitory factor (MIF) and extracellular MMP inducer in tumor cells (Hagemann et al.,
2005).
The paradoxical functions of TNF result from the existence of extensive crosstalk
among TNF-induced pathways. For instance, TNF induces apoptosis through extrinsic
and intrinsic pathways while it also enhances expression of anti-apoptotic proteins
through NF-κB activation. Activative caspase-8 resulting from TNF stimulation mediates
cell apoptosis and it also causes cleavage of the key NF-κB mediator RIP to terminate the
cell survival signal (Lin et al., 1999). The mitochondria-released Smac blocks IAPs,
leading to apoptosis. On the other hand, TNF induced NF-κB activation inhibits the
apoptotic JNK activation and induces expression of anti-apoptotic and antioxidant genes,
preventing cell death and promoting cancer cell proliferation (Wajant et al., 2003;
Kamata et al., 2005). Other factors, such as cell type, concurrent stimulation of other
cytokines, or the amount of reactive oxygen species (ROS) can shift the balance in favor
of one pathway or another. Therefore, the balance between TNF-induced pro- and antisurvival signalings determines diverse functions of the end result.
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E. Notch, Akt and NF-κB

1. Notch and NF-κB

So far, a number of reports have described the crosstalk between NF-κB and
Notch. The effect of Notch-1 regulation on NF-κB activity has been conflicting. It has
been suggested that Notch inhibits NF-κB activity in the nucleus via direct interaction
mediated by the N-terminal portion of Notch-1 (Guan et al., 1996; Wang et al., 2001).
Notch-1 was also shown to inhibit NF-κB activity by increasing IκBα expression via
derepressing CBF-1 repressing effect on IκBα promoter in hepatic stellate cell (Oakley et
al., 2003).
In contrast, more studies indicated that Notch receptors activate NF-κB. NF-κB
activation involves a group of components along the signal transduction pathway. In fact,
Notch has been shown to regulate NF-κB signaling components at multiple levels to
activate NF-κB activity.
First of all, at the level of IKK upstream kinase, Notch-3 has been demonstrated
to modulate PKC θ, which is a kinase upstream of IKK complex, to regulate NF-κB
activation in thymocytes and T lymphoma cells of Notch-3 transgenic mice. Notch-3 can
also increase association between IKKα and NIK, possibly leading to a further increase
of the overall NF-κB activation (Bellavia et al., 2000; Bellavia et al., 2002). Notch-1 has
been shown to activate Akt in many systems; we will discuss it in detail in later section.
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Secondly, at the level of IKK complex, it is known that Notch-3 forms a complex
with IKKα homodimers and activates cytoplasmic IKKα kinase activity (Bellavia et al.,
2000; Felli et al., 2005; Vacca et al., 2006). Notch signaling activation mediated by
Jagged-1 is reported to induce IKK kinase activity in human keratinocytes (Nickoloff et
al., 2002). Similar effects were observed in murine erythroleukemia (MEL) cells
undergoing erythroid differentiation (Jang et al., 2004). In this model, the authors showed
that exposure of MEL cells to stromal cells expressing Notch ligand Jagged-2 caused
rapid and short lived activation of NF-κB. Recently, it has been shown that
overexpression of Notch-1IC activates NF-κB by interacting with the IKKα/β
signalosome and enhancing IKKα/β kinase activity in a mouse model of T-cell acute
lymphoblastic leukemia (T-ALL) and in human T-ALL cells (Vilimas et al., 2007).
Finally, at the level of NF-κB subunits, several different mechanisms have been
elucidated: physical interaction between Notch-1 and p50/c-Rel; transcriptional
regulation of NF-κB subunits and NF-κB dependent genes by Notch-1.
It is revealed that Notch-1 physically interacts with p50/c-Rel complexes.
Through this interaction, Notch-1 competes with IκB α and prevents it from exporting
NF-κB to the cytoplasm and promotes nuclear translocation of NF-κB (Shin et al., 2006).
In addition to physical interaction, Notch-1 is also shown to activate NF-κB by
increasing transcription expression of NF-κB subunits and NF-κB dependent genes
(Cheng et al., 2001; Oswald et al., 1998). Potential CBF-1 binding sites have been
identified within the NF-κB sites in the promoter region of some genes, including the
mouse major histocompatibility complex, β2-microglobulin, interleukin (IL) 6, NF-κB2,
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and CYP2B1 (Brou et al., 1994; Israel et al., 1989; Kannabiran et al., 1997; Lee et al.,
2000; Oswald et al., 1998). A subset of NF-κB binding sites (GGGAAA) may also
contain an overlapping CBF-1 site (CTGGGA). Moreover, Oswald et al. (Oswald et al.,
1998) demonstrated that CBF-1 binds to NF-κB binding sites in Bcl-3, IκBα, IFN-β.
Cheng (Cheng et al., 2001) showed that Notch-1 upregulates the expression of p50, p65,
RelB and c-Rel NF-κB subunits in murine bone marrow hematopoietic precursors.
Conversely, reports have shown that NF-κB also regulates Notch dependent
signaling. c-Rel induced Jagged-1 expression, triggering the Notch signaling pathway in
neighboring cells (Bash et al., 1999). Sequestration of p65 by IκBα translocated nuclear
corepressor SMRT/N-CoR to the cytoplasm, abrogating SMRT/N-CoR mediated
repression of Notch dependent promoters (Espinosa et al., 2002; Espinosa et al., 2003).
IκBα was described to bind to the Hes-1 promoter and associate with transcriptional
repression (Aguilera et al., 2004). IKKα could alleviate this transcription repression,
presumably by phosphorylating IκB α. Nuclear IKKα also can phosphorylate SMRT on
CBF-1 dependent promoter (Fernandez-Majada et al., 2007), leading to uncontrolled
activation of Notch-mediated signaling. More recently, Notch-2 and NF-κB have been
reported to cooperate in marginal zone B-cell development. In this model, NF-κB
stimulates the expression of two known Notch targets, Hes-5 and Deltex-1 (Moran et al.,
2007).
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2. Notch and Akt

PI3K-Akt signaling pathway is involved in multiple cellular functions including
promoting cell growth, increasing glucose uptake and oxidation, cell cycle progression
and cell survival. The PI3K is activated by receptor tyrosine kinases and G protein
coupled

receptors

to

generate

phosphatidylinositol

triphosphate

(PIP3)

from

phosphatidylinositol 4,5 biphosphate (PIP2). The accumulation of PIP3 at the membrane
recruits the Akt kinase and induces its phosphorylation by PDK1 and the mTOR-Rictor
kinases at Thr 308 and Ser 473, respectively (Sarbassov et al., 2005). In turn, Akt
activates the phosphorylation of multiple downstream substrates including IKKα.
Signaling by the PI3K-Akt pathway is terminated by the PTEN phosphatase, which
dephosphorylates and thereby inactivates PIP3 (Bader et al., 2005).
Increasing number of reports demonstrate that Notch interplays with Akt in
various systems. Notch is able to activate Akt and also inhibit Akt activity depending on
the physiological context. In T-cells, Notch-1 has been shown to activate Akt via Src
family protein tyrosine kinase p56lck (Sade et al., 2004). Notch signals promote T-cell
precursors survival through maintenance of cellular metabolism via activation of the
PI3K-Akt signaling pathway (Ciofani and Zuniga-Pflucker, 2005). Active Notch-1
inhibits p53-induced apoptosis and sustains transformation by HPV 16 E6 and E7
oncogenes through a PI3K/Akt dependent pathway (Nair et al., 2003). In melanoma,
constitutive activation of Notch-1 drives primary melanoma toward a more aggressive
phenotype in vitro and in vivo by activating PI3K/Akt pathway (Liu et al., 2006).
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The mechanism by which Notch-1 activates has been studied. Notch-1 activates
Akt by decreasing PTEN (phosphatase and tensin homolog) expression through Hes1 and
Myc in TALL cells. Both Hes1 and Myc bind and regulate the PTEN promoter, with
Hes1 working as a strong transcriptional repressor and Myc as a weaker transcriptional
activator, so that the overall output downstream of Notch-1 activation is a controlled
downregulation of PTEN transcripts (Palomero et al., 2007). More recently,
Perumalsamy (Perumalsamy et al., 2009) showed another mechanism that cytoplasmic
but not nuclear Notch-1 blocks apoptosis triggered by nutrition deprivation in Hela cells
through mTOR, Rictor and Akt dependent signaling. The same effect was also observed
in the cytokine-deprived condition in activated T cells.
Given the crucial role of Notch-1 promoting cell survival via Akt dependent
signaling, inhibition of Notch-1 results in downregulation of PI3K/Akt activation and
induction of cell apoptosis. In T-ALL cells, downregulation of Notch-1 by siRNA
inhibits cell proliferation, induces cell cycle arrest and apoptosis by suppressing Akt
activity. Using GSI to block oxaliplatin-induced activation of Notch-1 signaling enhances
colon cancer cells chemosensitivity. This effect is achieved by prevention of induction of
prosurvival Akt signaling (Meng et al., 2009). In gliomas cells, Notch-1 silencing inhibits
cell growth, causes cell cycle arrest and apoptosis and reduces cell invasiveness by
downregulating EGFR，PI3K/Akt (Xu et al., 2009).
Notch-1 has also been documented to inhibit Akt signaling. Constitutively active
Notch-1 increases PTEN protein expression and leads to the loss of Akt phosphorylation
in 293 HEK cells (Chappell et al., 2005). Notch-1 inhibits endothelial cell proliferation
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by repressing MAPK and PI3K/Akt dependent pathway (Liu et al., 2006). Notch-1
inhibits Akt phosporylation in T cell activation as reported by Eagar (Eagar et al., 2004).
On the other hand, several studies have shown the regulation of Akt in Notch-1
signaling. Notch-1 is required for Akt to transform melanocytes in vitro and activated by
Akt through NF-κB activity (Bedogni et al., 2008). Inhibition of Akt results in the
decreased protein expression of Notch-1 (Calzavara et al., 2008).

3. Akt and NF-κB

NF-κB is an important downstream outcome of Akt activation. It is reported that
Akt is required for NF-κB activation induced by TNF-α (Ozes et al., 1999). Akt functions
through IKK to promote the transactivation potential and phosphorylation of NF-κB
(Madrid et al., 2001). Akt is proposed to promote metastasis and angiogenesis through
IKK in a manner that depends on NF-κB activation (Agarwal et al., 2005).

CHAPTER III
MATERIAL AND METHODS

A. MATERIALS

1. Antibodies

The following antibodies were obtained from Santa Cruz Biotechnology (Santa
Cruz, CA): Notch-1 (C-20), IκB-α (H-4), Akt1 (C-20), Pol II antibody (H-224), Notch-4
(H-225) normal mouse IgG rabbit IgG, goat IgG, secondary anti-mouse antibody. The
antibodies below were bought from Cell Signaling: active form of Notch-1 (Val1744), pIKKα/β (2681), p-Akt Ser 473 (D9E) and p-IκBα(5A5). The antibodies below were
obtained from IMGENEX (Sorrento Valley, CA): NF-κB p50 (IMG-5812A), p65 (IMG150A) and IKKα (IMG-136A). The antibodies below were obtained from Abcam
(Cambridge, MA): Human specific IKKα (ab4111) and IKKα (ab25108) for IP. The
secondary anti-goat antibody was purchased from Vector Laboratories (Burlingame, CA).
The secondary antibody anti-rabbit was from GE health care. The antibody against βactin (AC-15) was from Sigma-Aldrich.
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2. Cell culture

Caski and MDA-MB-231 cells from ATCC and LTK-Parental and LTK-Jagged-1
cells generously provided by Dr. G. Weinmaster (University of California at Los
Angeles, Los Angeles, CA), were cultured in DMEM with 10% FBS.

3. Drugs

Gamma secretase inhibitor (GSI) cbz-Leu-Leu-Nle-CHO was purchased from
Calbiochem (Cat# 565750). GSI MRK-003 was a kind gift from Dr. Peter Strack (Merck
Inc.). Wortmannin was purchased from Sigma-Aldrich. Drugs were dissolved in DMSO
and stored in aliquots at –20 oC. TNF-α (61606 BD Pharmingen) was aliquoted in BSA
(1mg/ml).

4. Plasmids and siRNA

The pcDNA-Notch1IC constructs have been obtained from Dr. Anthony
Capobianco, Cincinnati Childrends Hospital (Cincinnati, OH).
Dominant negative IKKα was kindly provided by G.E. Sonenshein, Boston
University School of Medicine (Boston, MA).
The NF-κB firefly luciferase construct was kindly provided by B.J. Nickoloff,
Loyola University Medical Center (Chicago, IL) and the Renilla Luiciferase construct
PRL-TK (Cat#: E2241) was purchased from Promega (Madison,WI).
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The CBF-1 luciferase construct was a generous gift from Dr. Tom Kadesch
(University of Pennsylvania, Philadelphia PA). Four wild type CBF-1 consensus repeats
were cloned in front of the minimal promoter and upstream the luicferase gene in the
pGL2-basic vector.
Full length Notch-1 tagged with Renilla at C-terminus was kindly provided by Dr.
Raphael Kopan (Washington University St. Louis, MO).
Control siRNA (sc-36869), Notch-1 (sc-36095) and IKKα siRNA (sc-29365)
were from Santa Cruz Biotechnology (Santa Cruz, CA).

5. Kits

RNeasy Mini kit, RNase-Free DNase set kit, QIAquick PCR purification kit and
QIA shredder were bought from Qiagen. First strand cDNA synthesis Kit was purchased
from Fermentase Life Science Co., EU.

B. Methods

1. Dual luciferase assay

Caski or MDA-MB-231 cells were plated on 24 well plate and transfected with
0.4 µg of NF-κB luciferase reporter or CBF-1 luciferase reporter/well and 0.02 µg pRLTK/well as the internal control. Luciferase assays (Dual-Luciferase Assay System,
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Promega) were performed 48 hrs after transfection. Cells were washed twice with 1×
PBS and lysed in 100 µl luciferase reporter buffer (Promega, Madison, WI). Ten µl of the
cell lysate was transferred to a 96-well plate and luciferase assays were performed using
the substrates Luciferin or Coelenterazine for Firefly luciferase or Renilla luciferase,
respectively (Dual-Luciferase Assay System, Promega). The luciferase activity was
quantified using a luminometer (Veritas, CA). The relative light units Luciferase values
were normalized against renilla luciferase activity. At least three independent
experiments were performed in duplicate.

2. Immunoprecipitation (IP), Co-Immunoprecipitation (Co-IP) and Quantitative
Renilla Co-IP

For IP, MDA-MB-231 cells together with either LTK-PAR or LTK-JAG were
lysed in RIPA buffer (50 mM Tris-Cl, pH 8.0, 150 mM NaCl, 0.1% sodium dodecyl
sµlfate (SDS), 1% Nonidet P-40 (NP-40)) supplemented with a cocktail of protease
inhibitors (Roche, IN) and (1×) phosphatase inhibitors (78420 pierce). The lysates were
incubated on ice for 30 mins and centrifuged at 13000 rpm for 10 mins. The supernatants
were precleared by incubating with 30 µl protein A/G beads (Calbiochem) for 1 hr with
shaking. The cell lysate was immunoprecipitated with 2 µg of antibodies overnight
followed by 2 hrs immunoprecipitation by 30 µl of beads. The beads were washed three
times in RIPA buffer and were then boiled in Laemmli buffer and assayed by Western
blot.
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For Co-IP, the procedure is similar to IP. The differences are in the buffers and
primary antibody used in the immunoblot. Lysis buffer contains 20 mM Hepes pH 7.9,
137 mM NaCl, 10 % glycerol, 1% NP40, 2 mM EDTA, and protease inhibitors. Washing
buffer has 20 mM Hepes pH 7.9, 137 mM NaCl, 10 % glycerol, 0.5% NP40, 2 mM
EDTA and protease inhibitors.
For Renilla Co-IP, quantiative Renilla immunoprecipitation was performed as
described (Vooijs et al., 2004) previously. CaSki cells were transfected with 2.0 µg of
Notch-1 luciferase construct. Forty-eight hours after transfection, cells were treated for
30 min with vehicle or TNF-α (10 ng/ml). The cells were washed with 2X PBS and lysed
in Co-IP buffer (0.2M KCl, 25mM HEPES, pH 7.4, 1% Nonidet P-40, and 0.2mM
EGTA) supplemented with a cocktail of protease inhibitors (Roche). The cell lysate was
immunoprecipitated with 2 µg of antibodies or correspondent control IgG for 2 hrs
followed by 2 hrs incubation with protein G plus/protein A Agarose beads (Calbiochem).
After washing the beads with Co-IP buffer, luciferase activity in washed pellets was
determined (Dual-Luciferase Assay System, Promega) and compared to total Renilla
luciferase activity (pellet plus combined supernatants). Data are representative of three
independent experiments, each conducted in triplicate.

3. Kinase assay

The kinase activity of the IKKα and the IKKβ subunits of the IKK complex was
measured by kinase assay. Briefly the treated and untreated cells were lysed in lysis
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buffer (20 mM HEPES, pH 7.4, 2 mM EGTA, 1% Triton X-100, 10% glycerol)
supplemented with protease inhibitor cocktail (Roche), 1 mM Na-orthovanadate, 50 mM
β-glycerophosphate and 1 mM DTT. The cell lysates were collected and pre-cleared with
protein A/G sepharose beads rotating for 1 hr. The subunits were immunoprecipitated
with antibodies specific to IKKα or IKKβ by using protein A/G sepharose beads. The
beads were then washed three times with lysis buffer. Then 20 µl of kinase buffer
supplemented with 10 µCuries of γ-P32 ATP and 2 µg of GST-IκBα substrate
(Millipore) was added to each tube. The tubes were incubated for 30 mins at 30 ºC with
gentle shaking. The reaction was stopped by addition of 4X Nupage LDS Sample buffer
(Invitrogen, CA) and the sample was boiled at 80 oC for 5 mins. The samples were spun
down, and the supernatant containing the substrates was then loaded and run on a 7% trisacetate gel and gels were dried for 2 hrs. The amount of phosphorylated substrate was
then detected and subjected to autoradiography.

4. Real time RT-PCR

Total RNA was isolated from either transfected or treated cells using RNeasy
Mini kit (Qiagen) following the manufacture’s directions. Reverse transcription was
performed with random hexamer primers or specific primers using the First strand cDNA
synthesis Kit (Fermentase Life Science Co., EU) according to the manual. cDNAs were
amplified by real time PCR using iTaqTM SYBR Green Supermix with ROX (Bio-RAd,
CA). Each reaction sample contained 12.5 ul Supermix, 0.25 µl of each primer at 50 µM,
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10 µl H2O and 2 µl cDNA. Each sample was run in triplicate in a 96-well Optical
Reaction plate (Applied Biosystems, CA). The PCR reaction conditions were: 50 oC for 2
mins, 95 oC for 5 mins, 35 cycles of (95 oC for 30 secs, 59 oC for 1 min, 72 oC for 1 min)
followed by dissociation step. The data were analyzed by utilizing the 7300 system
Software (Applied Biosystems, CA).
The primers used in real time PCR were: RPL13a forward and reverse
respectively: ACAAGATAGGGCCCTCCA AT; CATAGGAAGCTGGGAGCAAG;
cIAP-2

forward

and

reverse

AACACAGCTTCAGCTTCTTGC;

respectively:
A20

CCGGAAGAATAGAATGGCACT;

forward

and

reverse

respectively:

TATGGCTAACCGGAAACAGG; TCTCCTGCTCAGACACCCTT; IκBα forward and
reverse respectively: GAAGAAGGAGCGGCTACTGG;
CTGCAGCTCCTTGACCATCT.

5. Quantitative Chromatin Immunoprecipation (CHIP)

Quantitative ChIP analysis was carried out as described (Wu et al., 2005). Briefly,
MDA-MB-231 cells were crosslinked with 1% formaldehyde for 10 mins at room
temperature. Harvested cells were lysed in nucleus lysis buffer (1% SDS, 10 mM EDTA,
50 mM Tris-HCl, pH 8.1) for 10 mins. The lysate was sonicated on ice at 95% total
power for 6 cycles of 12 pulses each. Between sample sonications, the samples were kept
on ice to make sure low temperature. Lysates were centrifuged at 14,000 rpm for 10 mins
at 4°C, and the supernatant was taken. Nine times volume of dilution buffer (10 mM Tris-
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HCl, pH 8.1, 150 mM NaCl, 1 mM EDTA, 0.01% SDS, and 1% TritonX-100) based on
the volume of the supernatant was then added to the supernatant, creating the IP solution.
The IP solution was pre-cleared with 60 µl of Salmon Sperm DNA/Protein G
Agarose–50% Slurry (Upstate Biotechnology, VA) for 1 hr at 4°C with agitation.
Following pre-clear, the IP solution was incubated with the indicated antibodies
overnight.
The next day, immune complexes were recovered by incubation with 60 µl of
Salmon Sperm DNA/Protein G Agarose – 50% Slurry for 2 hrs with gentle rocking. The
agarose beads were pelleted by centrifugation for 2 mins at 2,000 rpm and washed for 5
mins for each wash at 4°C with rocking with the following buffers: one wash in Low
Salt Immune Complex Wash Buffer (0.1% SDS, 1% Triton X-100, 2 mM EDTA, 150
mM NaCl, 20 mM Tris-HCl (pH=8.0)), one wash in High Salt Immune Complex Wash
Buffer (0.1% SDS, 1% Triton X-100, 2 mM EDTA, 500 mM NaCl, 20 mM Tris-HCl
(pH=8.0)), one wash in LiCl Wash Buffer (0.25 M LiCl, 1% IGEPAL CA-630, 1%
sodium deoxycholate, 1 mM EDTA, 10 mM Tris-HCl (pH=8.0)), and two washes in TE
buffer (pH=8.0). After the final wash, the TE buffer was taken out by pipetting to insure
no leftover. 250 µl of freshly prepared Elution Buffer was (1% SDS, 0.1 M NaHCO3)
added to the beads at room temperature. The immuno-complex was eluted by rocking for
15 mins and collected. Elution was repeated as described, yielding a total volume of 500
µl. Five µl of 5 M NaCl and 1 µl of 20 mg/ml Proteinase K (Invitrogen, CA) were added
to each sample, which was incubated ovenight at 65°C to break the formaldehyde
crosslinks.
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The next day, DNA was recovered by using the QIAquick PCR purification kit
following the manufacturer’s instruction. The eluted DNA was analyzed by quantitative
real-time PCR with the indicated primer pairs. The amounts of products were determined
relative to a standard curve generated from a titration of input chromatin. Primers
designed to amplify the NF-κB-site on c-IAP2 promoter were: (Forward) 5TGTGTGGTTATTACCGCTGG-3 and (Reverse) 5-GCGAGTCTCACGCTGTCTTT-3;
primers

for

NF-κB-site

on

A20

promoter

were:

(Forward)

5-

CTGCAGAAAAACAACTGCGA and (Reverse) 5-GTGAGTCACCTGGGCATTTC-3.
PCR

was

also

performed

with

primers

for

β-globin

gene

(Forward)

CCAGCCTTATCCCAACCATA, (Reverse): TATCATGCCTCTTTGCACCA as an
internal control.

6. Transient DNA transfection and siRNA transfection

Transient DNA transfection: MDA-MB231 cells at 30-50% confluency were
transiently transfected using FuGENE 6 Transfection Reagent (Roche Diagnostics
Corporation, Indianapolis, IN) according to the manufacturer’s instructions. Briefly,
plasmid constructs (0.4-1 µg of DNA/well for 24-well plate or 6 µg of DNA for 8 cm
dish) were diluted into serum-free media and mixed with FuGENE 6 Transfection
Reagent (ratio of DNA and FuGENE 6: 1:3). Complexes were allowed to form for 15
mins at room temperature before adding to the cells, which were then incubated at 37 °C.
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Forty-eight hrs after transfection, the expression level of target protein was determined by
Western blot.
siRNA transfection: MDA-MB231 cells at 30-50% confluency were transiently
transfected using Lipofectamine RNAiMAX (Invitrogen, CA). We followed the
transfection protocol according to the manufacturer’s instruction. Briefly, Lipofectamine
RNAiMAX was incubated in Opti-MEM medium for 5 mins at room temperature. siRNA
were added to the Opti-MEM medium and incubated for 5 mins at room temperature. The
siRNA and Lipofectamine RNAiMAX complex were mixed together and incubated for
20 mins at room temperature. The mixture was then added to cells. Forty-eight hrs after
transfection, the expression level of target protein was determined by Western blot.

7. Western blots

Cells were washed twice with cold phosphate buffered saline (PBS) and collected
in PBS using a cell scraper. Cells were pelleted in a centrifuge at 5,000 rpm for 5 mins at
4 °C. Cell pellets were lysed in radio-immunoprecipitation assay buffer (RIPA; 50 mM
Tris-Cl, pH 8.0, 150 mM NaCl, 0.1% sodium dodecyl sµlfate (SDS), 1% Nonidet P-40
(NP-40)) supplemented with fresh deoxycholic acid (0.5%) and a cocktail of protease
inhibitors (Roche, IN) for 30 mins on ice. The lysates were kept on ice and sonicated at
50% total power on ice 4 times for 6 secs seconds each. Samples were then
microcentrifuged at 4 °C for 10 mins at 14000 rpm. The supernatant was collected and
protein concentration was determined using the BCA colorimetric assay (Pierce, IL).
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For Western blot analysis, equal amounts of protein extracted from each sample
(30-100 µg) were prepared by adding 4x sample buffer and 10x DTT (0.5 M) and
subjected to 7% SDS-PAGE. The samples were loaded into pre-casted 7% NuPAGE
Tris-acetate gel (Invitrogen). The resolved protein samples were transferred to
polyvinylidene difluoride membranes (Bio-Rad, Hercules, CA) by using Invitrogen’s
buffering system at 30 volts for 1 hr at room temperature. The membranes were blocked
with blocking buffer for 1 hr at room temperature. The membranes were then incubated
at 4 oC overnight in the primary antibody diluted in blocking buffer. Membranes were
washed 3 times in TBST for 10 mins each at room temperature followed by incubation in
horseradish peroxidase labeled secondary antibody also diluted in blocking buffer for one
hour at room temperature. The membrane blots were developed by chemiluminescent
reagents (Supersignal, Thermo Scientific, Rockford, IL) according to the manufacturer’s
instructions and exposed to Fujifilm intelligent dark box (LAS-3000). After multiple
probings of the membrane with different antibodies, the membranes were probed a final
time with anti-actin antibody to confirm equal loading of the proteins.

8. Statistical analysis

For two sample comparisons, two-tailed unpaired Student’s t tests were used with
α=0.05. When more than two samples were compared, one-way ANOVA was used
(Student-Newman-Keuls method for multiple comparisons), with α=0.05. Excel software
was used for statistical analysis.

CHAPTER IV
RESULTS

A. Aim 1: To determine whether Notch-1 activates NF-κB in cervical and ERbreast cancer.

1. Introduction

Breast and cervical cancer are two common cancers that severely endanger
women’s health. Cervical cancer was once the leading cause of death for women in the
United States. However, during the past few decades, largely due to widespread use of
the Papanicolaou test, incidence and mortality from cervical cancer have declined
significantly. Currently, breast cancer particularly estrogen receptor alpha negative (ER-)
breast cancer has become the leading cause of cancer related mortality in women
worldwide (Wildiers et al., 2007). Cervical and breast cancer screening programs have
been established to detect cancer in earlier stages and help decrease mortality for both
cancers. However, based on the data from WHO (2006), the fatality rate of breast and
cervical cancer is still ranked first and fifth respectively in cancer-related death， in
women globally. Continuous dedication to cancer research is urgently required to
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elucidate the cancer cell survival mechanism at the molecular level that is responsible for
disease aggressiveness and poor prognosis.
Emerging data indicate that misregulation of Notch-1 has been associated with
neoplastic transformation in cervical and breast cancer. In cervical cancer, increased
expressions of Notch-1 and Notch ligands were documented (Zagouras et al., 1995;
Daniel et al., 1997; Gray et al., 1999) and accumulation of Notch-1 and its ligand Jagged1 was found to be coincident with the progression of high-grade precursor lesions to
invasive cervical cancers (Veeraraghavalu et al., 2004). Not only in cervical cancer, but
also in a variety of human breast carcinomas, the elevated Notch signaling was also
observed (Reedijk et al., 2005; Stylianou et al., 2006). High level expression of Notch-1
and its ligand Jagged-1 predicted poor overall survival in breast cancer patients (Reedijk
et al., 2005; Dickson et al., 2007; Reedijk et al., 2008).
Increasing evidence reveals that inhibition of Notch-1 sensitizes cancer cells to
apoptosis, causes cell cycle arrest and decreases cellular transformation. Inhibiting Notch
signaling by antisense silencing in CaSki cervical cancer cells abolished proliferation and
anchorage-independent growth in vitro (Weijzen et al., 2002) and completely blocked the
growth of CaSki xenografts in vivo (Weijzen et al., 2003). Inhibition of Notch suppressed
breast tumors growth (Pece et al., 2004) and reverted the transformed phenotype of
human breast cancer cell lines, including the ER- breast cancer cell line MDA-MB-231
(Stylianou et al., 2006). Our lab also showed that Notch-1 knockdown by siRNA or GSI
caused G2 arrest and induced apoptosis in breast cancer cells.
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However, the mechanism whereby Notch-1 promotes cell survival and/or
proliferation and transformation is not clear. Accumulating reports show that NF-κB is
also deregulated in these two cancers and might be the downstream signaling effector of
Notch-1 to modulate cell survival and apoptosis. It was shown that activated Notch
signaling

was

accompanied

by elevated

NF-κB

activity as

determined

by

immunohistochemistry from cervical cancer patients’ samples. Constitutive activation of
NF-κB with nuclear accumulation of p50 and p65 has been described to be associated
with cervical cancer progression (Nair et al., 2003; Prusty et al., 2005). Aberrantly
regulated Notch and NF-κB activity are also concurrently found in ER- breast cancer.
Notch-1 and NF-κB activity are highly active in ER- breast cancer cell lines as well as
ER- breast tumors as compared to ER + counterparts. Elevated NF-κB activation in ERbreast cancer has been suggested to be responsible for chemoresistance and metastatic
growth. Here, we hypothesize that Notch-1 promotes cell survival by activating NF-κB
activity in cervical and ER- breast cancer.
Overall, previous literatures showed that Notch-1 was aberrantly regulated in
human cervical and ER- breast cancer and inhibiting Notch-1 sensitized cancer cells to
apoptosis. NF-κB was also deregulated in these two cancers and might be the
downstream signaling effector of Notch-1 to modulate cell survival and apoptosis. We
hypothesize that Notch-1 promotes cell survival by activating NF-κB activity in cervical
and ER- breast cancer. Therefore, we have the first Aim: Aim1: to determine whether
Notch-1 activates NF-κB in cervical and ER- breast cancer.
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2. Notch-1 activates NF-κB in cervical and ER- breast cancer.

To investigate whether Notch-1 activates NF-κB in cervical and ER- breast cancer
cells, we used the NF-κB driven luciferase reporter assay. We found that Notch-1 is
required and sufficient to activate NF-κB activity in cervical and ER- breast cancer.
Notch-1 silencing by siRNA resulted in approximately 50% decrease in NF-κB-driven
luciferase activity in both cervical cancer cells CaSki and ER- breast cancer MDA-MB231 cells at the basal level (Figure 4.1 A). In cervical cancer, Tumor Necrosis Factor
(TNF)–α has been implicated in both direct and indirect control of HPV infection. HPVharboring cervical keratinocytes constitutively produce active TNF-α (Malejczyk et al.,
1992), and increased localized production of TNF-α in cervical cancer has been observed
in vivo (Bequet-Romero and Lopez-Ocejo, 2000). Thus, we used TNF-α in CaSki cells to
mimic the in vivo physiological condition. About 50% inhibition was also observed in
TNF-α stimulated CaSki cells when transfected with Notch-1 siRNA (Figure 4.1 A). The
siRNA and overexpression transfections were validated by western blots using the same
lysates from used in luciferase experiments (Figure 4.1 A and C). In agreement with
siRNA data, treatment of CaSki and MDA-MB-231 cells with a γ-secretase inhibitor
(GSI) suppressed NF-κB reporter activity in a dose-dependent manner, with IC50 between
1 and 2 µM (Figure 4.1 B). These results suggest that Notch-1 is required to sustain the
constitutive active NF-κB activity in cervical and ER- breast cancer cells.
Conversely, we would like to determine how NF-κB activity changes when
Notch-1 signaling is up-regulated in the cells. Intracellular Notch-1 after cleavage is
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considered the active form of Notch-1. A plasmid encoding the intracellular Notch-1 was
utilized to up-regulate Notch-1 activity. CaSki and MDA-MB-231 cells were transiently
transfected with the active form of Notch-1 NIC. Overexpression of Notch-1 NIC led to a
dose-dependent increase of NF-κB reporter activity up to a transfection dose of 0.2 µg
plasmid DNA/105 cells (Figure 4.1C) in both cell lines. However, higher levels of Notch1 expression resulted in lower stimulation, consistent with published observations in
Jurkat cells (Guan et al., 1996; Wang et al., 2001). Representative western blots showed
the transfection result of 0.2 µg plasmid DNA/105 cells. The data indicate that Notch-1 is
not only required for full NF-κB activity but also sufficient to activate NF-κB activity in
cervical cancer CaSki cells and ER- breast cancer MDA-MB-231 cells.

3. Conclusion of Aim 1

In Aim 1, we monitored NF-κB activity under the conditions of either overexpressing Notch-1 or silencing Notch-1 by siRNA in both cervical cancer CaSki and
ER- breast cancer MDA-MB-231 cells. It is found that down-regulation of Notch-1
causes a decrease in NF-κB dependent transcription activity and activation of Notch-1
leads to an increase in NF-κB activity in both cells. In a word, data from Aim1 showed
that Notch-1 activates NF-κB activity in cervical cancer CaSki cells and ER- breast
cancer MDA-MB-231 cells.
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Figure 4.1: Notch-1 activates NF-κB activity in CaSki and MDA-MB-231 cells.
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Figure 4.1: Notch-1 activates NF-κB activity in CaSki and MDA-MB-231 cells. (A) Cells were transfected
with Control siRNA (CTL) or Notch-1 (N-1) siRNA. Twenty-four hrs later, they were transfected with NFκB-luciferase reporter plasmid plus pTK-Renilla luciferase plasmid as internal controls. TNF-α was added to
the medium 30 mins before harvest. (B) Cells were transfected with NF-κB-luciferase reporter plasmid plus
pTK-Renilla luciferase plasmid. Twenty-four hrs after transfection, cells were treated with either DMSO or
GSI with indicated doses for time shown (C) Cells were cotransfected with NF-κB-luciferase reporter plasmid
plus pTK-Renilla luciferase plasmid as well as expression plasmid encoding intracellular Notch-1 NIC. The
effects of Notch signaling modulation on NF-κB transcriptional activity were assessed by monitoring NF-κB
promoter-driven luciferase activity. Relative luciferase activity was calculated considering 1.0 as the activity
of cells transfected with empty vector. *P≤ 0.05. Western blots from (A) show the effective downregulation of
Notch-1 and Western blots from (C) show the overexpression of Notch-1 at 0.2 ug/105 cells. Data are
representative of three independent experiments, each conducted in triplicate.

72

B. Aim 2: To characterize the mechanism by which Notch-1 activates NF-κB in
cervical cancer CaSki cells: specifically determine whether Notch-1 interacts with
IKKα and activates IKKα/β kinase activity.

1. Introduction

Since we knew from the results of Aim1 that Notch-1 is not only required for full
NF-κB activity but also sufficient to activate NF-κB activity in cervical cancer CaSki
cells and ER- breast cancer MDA-MB-231 cells, we asked what is the mechanism by
which Notch-1activates NF-κB activity in cervical cancer CaSki cells?
First of all, we looked at the classical NF-κB signaling transduction cascade. NFκB subunits are sequestered in the cytoplasm by binding to inhibitory proteins (IκBs).
This inhibition can be released by phosphorylation of IκBs by the IKK complex,
consisting of IKKα, IKKβ and IKKγ. IKK complex could be activated by numerous
stimuli such as cytokines, chemokines, mitogens, and bacterial and viral infection.
Phosphorylation of IκBs results in degradation of IκBs and NF-κB subunits are allowed
to translocate to the nucleus and bind to NF-κB consensus sequence to rapidly
transactivate NF-κB target gene transcription. Therefore, there are multiple levels of NFκB activity regulation modulated by IKK upstream kinases, IKK complex, IκBs and NFκB subunits.
In fact, Notch has been shown to regulate NF-κB signaling components at
multiple levels to activate NF-κB activity. At the level of IKK upstream kinase, Notch-3
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has been demonstrated to modulate PKC θ (Bellavia et al., 2000; Felli et al., 2005; Vacca
et al., 2006) to regulate NF-κB activation in thymocytes and T lymphoma cells of Notch3 transgenic mice. Notch-1 has been shown to activate Akt which also sits upstream of
IKK in a variety of cellular systems (Nair et al., 2003; Liu et al., 2006; Graziani et al.,
2008; Meng et al., 2009).
Secondly, at the level of IKK complex, it is known that Notch-3 forms a complex
with IKKα homodimers and activates cytoplasmic IKKα kinase activity (Bellavia et al.,
2000; Felli et al., 2005; Vacca et al., 2006). Notch signaling activation mediated by
Jagged-1 is reported to induce IKK kinase activity in human keratinocytes (Nickoloff et
al., 2002). Recently, it has been shown that overexpression of intracellular Notch-1 NIC
activates NF-κB by interacting with the IKKα/β signalosome and enhancing IKKα/β
kinase activity in a mouse model of T-cell acute lymphoblastic leukemia (T-ALL) and in
human T-ALL cells (Vilimas et al., 2007).
At last, at the level of NF-κB subunits, several different mechanisms have been
elucidated: physical interaction between Notch-1 and p50/c-Rel; transcriptional
regulation of NF-κB subunits and NF-κB dependent genes by Notch-1. It was found that
Notch-1 physically interacts with p50/c-Rel complexes. Through this interaction, Notch-1
competes with IκBα and prevents it from exporting NF-κB to the cytoplasm and
promotes nuclear translocation of NF-κB (Shin et al., 2006). In addition to physical
interaction, Notch-1 is also shown to activate NF-κB by increasing transcription
expression of NF-κB subunits and NF-κB dependent genes (Cheng et al., 2001; Oswald
et al., 1998).
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Given the regulation could occur on multiple levels, we chose to focus first on
one regulation level: the activation of IKK complex. We hypothesize that Notch-1
interacts with IKKα/β and activates IKKα/β kinase activity to regulate NF-κB activity in
CaSki cells.

2. Notch-1 interacts with IKKα/β kinase in cervical cancer CaSki cells.

To test the hypothesis that Notch-1 interacts with IKKα/β to regulate NF-κB
activity in CaSki cells, the traditional Co-IPs (Co-immunoprecipitations) were conducted.
Figure 4.2 A shows that IKKα could be readily immunoprecipitated from total
cell extracts with Notch-1 antibody indicating the interaction between Notch-1 and IKKα.
On the other hand, reverse immunoprecipitations with IKKα antibodies were also carried
out to test the association. IKKα immunoprecipitations bring down a Notch-1 band
migrating at approximately 98 kDa in both total and nuclear extracts. The identity of the
Notch-1 form interacting with IKKα was determined by detecting Notch-1 with a specific
antibody against active Notch-1 NIC (Cell Signaling, Danvers, MA, USA) that does not
recognize uncleaved Notch-1. The same band was also immunoprecipitated by Notch-1
C-terminal antibodies (Santa Cruz) from nuclear lysate. This indicates that active
intracellular Notch-1 interacts with IKKα. The fact that Notch-1 co-immunoprecipitates
with IKKα in CaSki total cell extracts and nuclear extracts suggests a possible role of
Notch-1 in modulating the cytoplasmic and nuclear functions of IKKα (Figure 4.2 B).
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To confirm the interaction, we used a quantitative immunoprecipitation assay
described by Vooijs et al (Vooijs et al., 2004). This assay uses a full-length Notch-1
construct tagged at the C terminus with Renilla luciferase. By measuring luciferase
activity specifically immunoprecipitated with antibodies to putative interacting proteins,
this assay allows us to quantify putative interactions in a way not dependent on western
blotting. Using this assay, Notch-1 was reproducibly immunoprecipitated with IKKα
antibodies in CaSki cells treated with vehicle or TNF-α for 30 mins (Figures 4.2 C). This
assay consistently detected a specific interaction with IKK β in TNF-α treated cells,
although we didn’t observe the interaction between Notch-1 and IKK β in vehicle-treated
cells (Figure 4.2 C and D). This may suggest that TNF-α affects the composition or
stability of the IKK/Notch-1-containing complexes. Taken together, these data provide
evidence that Notch-1 interacts with IKKα in cervical cancer CaSki cells.

3. Notch-1 activates IKKα/β kinase activity in cervical cancer CaSki cells.

In order to test the functional consequence of association between Notch-1 and
IKK complex, we tested the IKK complex kinase activity from whole cell lysates by in
vitro immunoprecipitation kinase assays using a commercially available glutathione Stransferase-full-length IκBα fusion protein as a substrate. Figure 4.3A shows that an IκBα
kinase activity could be immunoprecipitated with antibodies to IKKα, IKKβ or Notch-1.
Notch-1 knockdown did not inhibit basal IKKα- or IKKβ-immunoprecipitated kinase
activity, but did inhibit basal Notch-1-associated activity. In TNF-α-stimulated cells,
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Notch-1 knockdown markedly inhibited IκBα kinase activity immunoprecipitated with
IKKα, IKKβ or Notch-1. TNF-α increased only the kinase activity immunoprecipitated
with IKKβ antibodies, but not that immunoprecipitated with IKKα and Notch-1
antibodies. Consistent with the siRNA data, GSI treatment also inhibits IKKα, IKKβ, and
Notch-1 immunoprecipitated kinase activity in a dose dependent manner in the presence
of TNF-α. These results indicate that endogenous Notch-1 is indispensable for NF-κB
activation and Notch-1 regulates IKK complex activity in TNF-α-stimulated CaSki cells.
Besides in vitro kinase assay, we also explored endogenous IκBα phosphorylation
by western blotting, which was also an assessment to show the IKK complex activity.
Figure 4.4 A shows that siRNA-mediated knockdown of Notch-1 for 48 hrs reduced the
basal levels of endogenous IκBα. Phospho-IκBα was very low under basal conditions and
was also decreased compared to the control, most likely as a consequence of lower total
protein levels. However, after 1 hr TNF-α stimulation, the phosphorylation of
endogenous IκBα was virtually abolished by Notch-1 siRNA, and total IκBα levels were
comparable to control. We interpreted this data to indicate that Notch-1 knockdown for
48 hrs inhibits basal NF-κB activity by undetermined mechanisms, reducing expression
of NF-κB targets including IκBα (Oakley et al., 2003). After TNF-α stimulation, Notch-1
is required for IKK signalosome activation and IκBα phosphorylation, and Notch-1
knockdown prevents IκBα phosphorylation.
Additionally, we also suppressed the Notch signaling pharmaceutically by using
GSI for 18 hrs, which blocks the final cleavage needed for Notch activation. Under these
conditions, GSI did not significantly affect total IκBα expression, but like Notch-1
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siRNA, GSI inhibited TNF-α-stimulated IκBα phosphorylation, which at 60 mins was
abolished (Figure 4.4 B). These results indicate that endogenous Notch-1 modulates NFκB activity in TNF-α stimulated CaSki cells at least in part by physically interacting with
the IKK signalosome and regulating its IKK kinase activity.

4. Conclusion of Aim 2

In Aim 2, we showed that the Notch-1 associates with IKK complex by using
traditional Co-IP and quantitative Co-IP. Notch-1 regulates IKK complex kinase activity
in response to TNF-α stimulation in CaSki cells as demonstrated by the results from
kinase assay and western blotting of phospho-IκBα. In summary, Notch-1 activates NFκB activity possibly by interacting with IKKα/β and regulating IKKα/β kinase activity in
CaSki cells stimulated with TNF-α.
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Figure 4.2: Notch-1 associates with IKKα and the IKK signalosome in CaSki cells.
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Figure 4.2: Notch-1 associates with IKKα and the IKK signalosome in CaSki cells. (A) Total cell
lysates (TCLs) were immunoprecipitated (IP) with Notch-1 antibody from Santa Cruz (C-20))
and analysed by western blotting (WB) for endogenous IKKα . Non-immune homologous IgG
was used as negative control. (B) Reverse immunoprecipitation with IKKα antibody or control
IgG in TCLs or nuclear extract (NL) of CaSki cells and detected with antibody specific to active
Notch-1 NIC (Cell Signaling 2421). Immunoprecipitation with Notch-1 Santa Cruz C-20
confirmed band identity (rightmost lane). (C,D) Quantitative reverse immunoprecipitation in
which cells were transfected with Notch-1/Renilla chimeric construct (Vooijs et al., 2004). Fortyeight hours after transfection, cells were treated for 30 mins with vehicle or TNF-α (10 ng/ml).
Cells were lysed and immunoprecipitations were carried out with antibodies to IKKα , IKKβ or
control IgG. Renilla luciferase activity (RLU) in washed pellets was determined and compared to
total Renilla luciferase activity (pellet plus combined supernatants). Data are representative of
three independent experiments. *P< 0.05 compared to IgG.
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Figure 4.3: Notch-1 regulates IKKα/β kinase activity in CaSki cells.
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Figure 4.3: Notch-1 regulates IKKα/β kinase activity in CaSki cells. (A) CaSki cells were
transiently transfected with either Control (CTL) or Notch-1 (N-1) siRNA. Forty-eight hrs
post-transfection, cells were treated with or without TNF-α (10 ng/ml) for 30 mins.
Knockdown was verified by western blotting. For each condition, 500 mg whole-cell
extract was immunoprecipitated with antibodies to IKKα, IKKβ or Notch-1 (C-20 Santa
Cruz). Kinase activity was determined using glutathione S-transferase-IκBα as a substrate,
followed by SDS–polyacrylamide gel electrophoresis and autoradiography. (B) Cells were
treated with either DMSO or different doses of GSI (µM) for 18 hrs and treated with
TNF-α 10 ng/ml for 30 mins before harvest. The kinase assay was conducted the same as
in (A). Data are representative of three independent experiments.
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Figure 4.4: Inhibition of Notch-1 decreases IKKα/β kinase activity
in CaSki cells.
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Figure 4.4: Inhibition of Notch-1 decreases IKKα/β kinase activity in CaSki cells. (A) CaSki
cells were transiently transfected with either Control siRNA (CTL) or Notch-1 (N-1) siRNA.
Forty-eight hrs post-transfection, cells were treated with or without TNF-α (10 ng/ml) for 30 or
60 mins and analysed by western blotting for phospho-IκBα (p-IκBα) and total IκBα. (B)
CaSki cells were treated for 18 hrs with vehicle (DMSO) or 2 µM GSI and then stimulated
with vehicle or TNF-α (10 ng/ml) for 30 or 60 mins and analysed by western blotting for
phospho-IκBα and total IκBα. (C) MDA-MB-231 cells have a more transient response to TNFα, which is different from that in CaSki cells. Western blot of MDA-MB-231 cells transfected
with either Control siRNA (CTL) or Notch-1 siRNA (N-1). Forty-eight hrs after transfection,
cells were treated with TNF-α 10 ng/ml for 0 min, 30 mins before protein extraction. Data are
representative of three independent experiments.
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C. Aim 3: To elucidate the mechanism by which Notch-1 activates NF-κB activity in
ER- breast cancer MDA-MB-231 cells.

1. Introduction

We knew that endogenous Notch-1 modulates NF-κB activity in CaSki cells at
least in part by physically interacting with the IKK signalosome and regulating its IKK
kinase activity. In order to elucidate the mechanism by which Notch-1 activates NF-κB
activity in ER- breast cancer, we first tested if Notch-1 modulates NF-κB activity by
physically interacting with the IKK signalosome as in CaSki cells.
However, we didn’t observe physical interactions between Notch-1 and IKKα/β
and we didn’t see a reduction of IKKα/β kinase activity when cells were transfected with
Notch-1 siRNA and treated with TNF-α for 30 mins, the same conditions that were used
in CaSki cells. In addition, we found that the stimulation of NF-κB activity by TNF-α in
MDA-MB-231 cells was more transient than that in CaSki cells. Specifically, in MDAMB-231 cells, the phosphorylation of IκBα was barely detectable at 30 mins time point
and total IκBα was degraded at 30 mins in both control and Notch-1 siRNA treated cells.
This indicates that phosphorylation of IκBα occured much earlier than 30 mins (Figure
4.4 B). While in CaSki cells, as shown in Figure 4.4 A, IκBα was phosphorylated at 30
mins time point and the phosphoryaltion continued to be accumulated after 1 hr TNF-α
stimulation. At 1 hr time point, the total IκBα was still present in both control and Notch-
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1 siRNA transfected cells. Taken together, it suggests that MDA-MB-231 cells have a
much more transient NF-κB activation in response to TNF-α stimulation.
These different responses to TNF-α stimulation from two cell lines suggest that
Notch-1 may utilize an alternative mechanism to regulate NF-κB activity in MDA-MB231 cells. As we discussed previously in Aim2, there are multiple layers of regulation on
NF-κB activity. Which level does Notch-1 regulate NF-κB activity in MDA-MB-231
cells?

2. Both Notch-1 and IKKα are required for a subset of NF-κB dependent gene
expression.

MDA-MB-231 cells may use a different mechanism from CaSki cells to modulate
NF-κB activity. In order to explore the mechanism accounting for Notch-1 regulation of
NF-κB in ER- breast cancer, we started to explore the gene expression profiles from
microarray data in MDA-MB-231 cells treated with either Notch-1 siRNA or GSI. A
panel of NF-κB dependent genes is shown to be regulated by Notch-1. Table1
summarizes the list of genes that are down-regulated by Notch-1 siRNA compared to
control siRNA. There are genes involved in cell cycle progression, such as cyclin D1,
bcl-3; cell differentiation and cell to cell communication, such as interleukin 11; cell
apoptosis such as c-IAP2; NF-κB regulator such as IκBα and A20.
We chose to study three important NF-κB dependent genes: cIAP-2, IκBα, and
A20. cIAP-2 (cellular inhibitor of apoptosis protein) is one of the anti-apoptotic proteins
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regulated by NF-κB. Recent evidence indicated that cIAP-2 was frequently
overexpressed in cancer and its expression level was implicated in contributing to
tumorigenesis, chemoresistance, disease progression and poor patient survival (Hunter et
al., 2007). In addition, Notch-1 and IKKα have been shown to be recruited to the cIAP-2
and IκBα promoters in CaSki cells (Song et al., 2008). The gene expression of A20 is
also transcriptionally activated through activation of NF-κB. High A20 expression has
also been shown to confer breast cancer cells resistance to apoptosis induced by TNF-α.
A20 is highly expressed in tamoxifen resistant cells and moreover it is over-expressed in
more aggressive breast tumors (ER-, PR- and high histological grade). A20 is proposed to
be a good marker for tumor aggressiveness in breast cancer (Vendrell et al., 2007).

Table1: Notch-1 regulates a subset of NF-κB dependent genes
Genes
BCL3
BIRC3 (c-IAP2)
CASP1
CCND1
GJA1
HMOX1
ICAM1
IL11
PLAU
TLR4
TNFIAP3 (A20)
NFKBIA (IκBα)

Fold reduction
0.54
0.63
0.61
0.58
0.68
0.64
0.73
0.46
0.8
0.65
0.68
0.8
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Figure 4.5: Notch-1 and IKKα are both required for a subset of
NF-κB dependent gene expression in MDA-MB-231 cells.
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Figure 4.5: Notch-1 and IKKα are both required for a subset of NF-κB dependent gene expression in
MDA-MB-231 cells. (A) MDA-MB-231 cells were transfected with either Control siRNA (CTL),
Notch-1 siRNA (N-1 siRNA) or IKKα siRNA. Cells were harvested and RNAs were extracted.
Reverse transcription and quantitative real time PCR were performed. Data were normalized to
RPL13a and the relative transcript level of cells transfected with Control siRNA was set as 1. Other
transcript levels were compared to the basal line. (B) Notch-1 and IKKα siRNA transfection were
validated by Western blot.

To validate microarray data and investigate the functional role of Notch-1 in NFκB activation in MDA-MB-231 cells, an independent quantitative RT-PCR was
performed. Figure 4.5 shows that Notch-1 siRNA caused 50%, 20% and 80% reduction
of cIAP-2, IκBα and A20 expression respectively. This is consistent with the microarray
data. IKKα siRNA also results in significant reduction of three genes expression. This
suggests that Notch-1 and IKKα are required for the expression of a subset of NF-κB
dependent genes.
We also studied gene expression upon activation of Notch signaling by
coculturing MDA-MB-231 cells with mouse fibroblasts expressing high level of Jagged-1
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(LTK-JAG). We chose this method because the coculture mimics the in vivo Notch
activation by ligands interaction from adjacent stromal cells (Sade et al., 2004). Also,
relevant to the biology of breast cancer, a high level of Jagged-1 was shown to be
associated with poor patient survival (Reedijk et al., 2005). We tested cIAP-2, IκBα, and
A20 transcript levels under coculture conditions using real time PCR with human specific
primers. cIAP-2, IκBα, and A20 transcript levels were induced dramatically in LTK-JAG
cocultured cells compared to that cocultured with parental cell (LTK-PAR) (Figure 4.6
A). It suggests that Notch-1 activation mediated by Jagged-1 activates a subset of NF-κB
dependent gene expression.
To determine the functional role of Notch-1 and IKKα in LTK-JAG coculture
mediated induction of NF-κB target gene expression, Notch-1 and IKKα were knocked
down by specific siRNAs respectively. The gene expression of cIAP-2, IκBα, and A20 in
the LTK-JAG coculture mediated induction was reduced markedly by either Notch-1
siRNA or IKKα siRNA, showing the requirement of both proteins in the gene activation
mediated by LTK-JAG coculture (Figure 4.6 B-D). Interestingly, the induction is
independent of the presence of another Notch family member Notch-4, confirming the
specific involvement of Notch-1 and IKKα in the activation of target genes mediated by
LTK-JAG coculture (Figure 4.6 B-D).
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Figure 4.6: Coculture of MDA-MB-231 cells with LTK-JAG induces a
subset of NF-κB dependent gene expression.
A

8

*

B
B LTK-PAR

*
4

6
5

LTK-JAG

6

Relative transcript level

B

4

cIAP-2 transcript level
CTL
N-1 siRNA
IKKα siRNA
N-4 siRNA

#

3

*

2

#

2
1

0

0

cIAP-2

IκBα

A20

PAR

IκBα transcript level
C

A20 transcript level

10

8

D

CTL
N-1 siRNA
IKKα siRNA
N-4 siRNA

JAG

5

4

#

CTL
N-1 siRNA
IKKα siRNA
N-4 siRNA

#

#

3

6

#
4

2

2

1

0

0

PAR
E

JAG

PAR

JAG

Western Blot
CTL IKKα

siRNA: CTL N-1

CTL N-4

N-1

IKKα

N-4

Actin

Actin

Actin

Figure 4.6: Coculture of MDA-MB-231 cells with LTK-JAG induces a subset of NF-κB
dependent gene expression. (A) MDA-MB-231 cells were cocultured with mouse fibroblast
parental LTK cells (PAR) or LTK cells with high expression of Jagged-1 (JAG) for 4 hrs. (BE) MDA-MB-231 cells were transfected with either Control siRNA (CTL), Notch-1(N-1),
Notch-4 (N-4) or IKKα siRNA. Forty-eight hrs after transfection, cells were cocultured with
LTK-PAR or LTK-JAG for 4 hrs. The relative transcript levels were determined. (E) Notch-1,
Notch-4, and IKKα siRNA transfection were validated by Western blot. Data are
representative of three independent experiments. * P< 0.05 compared to LTK-PAR; # P <
0.05 compared to CTL cocultured with LTK-JAG.
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3. Notch-1 activation mediated by Jagged-1 induces NF-κB subunits and Notch-1
recruitment to NF-κB dependent gene promoters.

Understanding that Notch-1 activates NF-κB activity and both Notch-1 and IKKα
are required for the expression of a subset of NF-κB dependent genes, we come back to
the original question: what is the prominent mechanism responsible for the Notch-1
regulation of NF-κB dependent genes in MDA-MB-231 cells? We knew that the physical
interaction between Notch-1 and IKK is not prominent in MDA-MB-231 cells and we
turned to the canonical Notch-1 and novel IKKα signaling pathway for clues. As a wellknown transcription factor, Notch-1 activates expression of target genes by binding to
CBF-1, a DNA binding protein, and converting CBF-1 from a repressor to an activator.
Binding of Notch-1 to CBF-1 facilitates the recruitment of transcription coactivators to
target gene promoters. Not only does Notch-1 have nuclear function IKKα does too. On
the cIAP-2 promoter, IKKα has been shown to have nuclear kinase function to activate
gene transcription by phosphorylating corepressor SMRT (silencing mediator of retinoid
and thyroid hormone receptors) (Hoberg et al., 2004; Hoberg et al., 2006). We found that
Notch-1 and IKKα were recruited to NF-κB dependent genes cIAP-2 and IκBα promoter
in Caski cells. Furthermore, the IKKα recruitment was Notch-1 dependent on both
promoters (Song et al., 2008). This prompted us to hypothesize that Notch-1 and IKKα
together may exert regulation on NF-κB dependent gene promoters in MDA-MB-231
cells. Therefore, we explored the recruitment of Notch-1, IKKα and NF-κB on NF-κB
dependent gene promoters in MDA-MB-231 cells.
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It is well known that NF-κB subunits are sequestered in the cytoplasm by IκBs.
Activation of NF-κB requires degradation of IκBs, translocation of NF-κB subunits to the
nucleus and transactivation of gene transcriptions. Since the cIAP-2 and A20 are induced
remarkably by Jagged-1 mediated activation of Notch-1, NF-κB subunits are expected to
be recruited to these promoters after coculture. We observed that NF-κB subunits p50 and
p65 were recruited to cIAP-2 and A20 promoters prominently after about 3 hrs only when
cocultured with LTK-JAG but not LTK-PAR as shown by quantitative ChIP experiments.
The recruitment was abolished if we knocked down Notch-1, indicating the critical role
of Notch-1 in recruiting or retaining NF-κB subunits to the gene promoters (Figure 4.7 A,
B). Moreover, we found that Notch-1 was also recruited to cIAP-2 promoter at this time
point and this association disappeared if Notch-1 siRNA was transfected, confirming the
specificity of immunoprecipitation (Figure 4.8)
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Figure 4.7: Coculture of MDA-MB-231 cells with LTK-JAG induces p50,
p65 recruitment to the cIAP-2 and A20 promoter.
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Figure 4.7: Coculture of MDA-MB-231 cells with LTK-JAG induces p50, p65
recruitment to the cIAP-2 and A20 promoter. (A-B) MDA-MB-231 cells were
transfected with Control (CTL) or Notch-1 siRNA (N-1 siRNA) and 48 hrs later
cocultured with mouse parental LTK cells (PAR) or LTK cells with high expression of
Jagged-1 (JAG) for 2 hrs and 45 mins. ChIP assays against specific antibodies were
performed. All ChIP data were expressed as relative fold induction of specific antibody
over IgG control. All data were normalized to the internal control: unspecific binding to
β-globin intron sequence. *P <0.05 compared to CTL cocultured with LTK-PAR. (C)
Western blot of MDA-MB-231 transfected with Control (CTL) or Notch-1 siRNA (N-1
siRNA). Data are representative of three independent experiments.
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Figure 4.8: Coculture of MDA-MB-231 cells with LTK-JAG induces
Notch-1 recruitment to the cIAP-2 promoter.
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Figure 4.8: Coculture of MDA-MB-231 cells with LTK-JAG induces Notch-1
recruitment to the cIAP-2 promoter. (A) MDA-MB-231 cells were cocultured with
mouse parental LTK cells (PAR) or LTK cells with high expression of Jagged-1 (JAG)
for the indicated time. (B) MDA-MB-231 cells were transfected with Control siRNA
(CTL) or Notch-1 siRNA (N-1 siRNA) and 48 hrs later cocultured with mouse parental
LTK cells (PAR) or LTK cells with high expression of Jagged-1 (JAG) for 2 hrs and 45
mins. ChIP assays against specific antibodies were performed. All ChIP data were
expressed as relative fold induction of specific antibody over IgG control. All data were
normalized to the internal control: unspecific binding to β-globin intron sequence. *P
<0.05 compared to LTK-PAR. Data are representative of three independent experiments.

4. Notch-1 activation mediated by Jagged-1 induces IKKα recruitment to NF-κB
dependent gene cIAP-2 promoter.

IKKα has nuclear kinase activities independent of the IKK complex. IKKα has
been shown to recruit to cIAP-2 promoter and phosphorylate corepressor SMRT and
release SMRT from the promoter thereby de-repressing transcription (Hoberg et al.,
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2004; Hoberg et al., 2006). We previously found that IKKα and Notch-1 are recruited to
the cIAP-2 promoter and IKKα recruitment is Notch-1 dependent in CaSki cells (Song et
al., 2008). Since we found that Notch-1 is recruited to the cIAP-2 promoter in MDA-MB231, we were wondering if IKKα is also associated with the cIAP-2 promoter together
with Notch-1 in these cells. Here, we failed to immunoprecipitate IKKα on cIAP-2
promoter at 3 hrs time point after coculture when Notch-1 is prominently associated with
cIAP-2 promoter. However, IKKα was found to be recruited at an earlier time point, 1 hr
after coculture, when Notch-1 was minimally recruited to the promoter (Figure 4.8 A and
4.9 A). It should be noted that the induced IKKα occupancy also required Notch-1 as
illustrated in Figure 4.9 B, suggesting that Notch-1 activation mediated by Jagged-1 is
necessary for IKKα recruitment.
IKKα nuclear kinase activity has been demonstrated to facilitate NF-κB subunits
recruitment to the cIAP-2 promoter (Hoberg et al., 2006). We inhibited IKKα kinase
activity by transfecting cells with dominant negative IKKα. Since IKKβ kinase is
predominantly responsible for cytoplasmic IKK complex activity, applying dominant
negative IKKα inhibits IKKα activity mostly while retaining normal IKKβ kinase activity.
Figure 4.9 D illustrates that induced NF-κB subunits recruitment to the cIAP-2 promoter
was inhibited by dominant negative IKKα, indicating that IKKα kinase activity was
required for the induced NF-κB subunits recruitment to the cIAP-2 promoter.
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Figure 4.9: Coculture of MDA-MB-231 cells with LTK-JAG induces IKKα
recruitment to the cIAP-2 promoter.
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Figure 4.9: Coculture of MDA-MB-231 cells with LTK-JAG induces IKKα recruitment
to the cIAP-2 promoter. (A) MDA-MB-231 cells were cocultured with mouse parental
LTK cells (PAR) or LTK cells with high expression of Jagged-1 (JAG) for the indicated
time. (B) MDA-MB-231 cells were transfected with Control (CTL) or Notch-1 siRNA
(N-1 siRNA) and 48 hrs later cocultured with mouse parental LTK cells (LTK-PAR) or
LTK cells with high expression of Jagged-1 (LTK-JAG) for 1 hr. (C) Western blot of
MDA-MB-231 transfected with Control (CTL) or Notch-1 siRNA (N-1 siRNA). (D)
MDA-MB-231 cells were transfected with EV or IKKα dominant negative construct
(IKKα DN). Forty-eight hrs later cells were cocultured with PAR or JAG for 2 hrs and 45
mins. ChIP assays against specific antibodies were performed. All ChIP data were
expressed as relative fold induction of specific antibody over IgG control. All data were
normalized to the internal control: unspecific binding to β-globin intron sequence. *P
<0.05 compared to LTK-PAR. Data are representative of three independent experiments.
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5. Notch-1 is recruited to the cIAP-2 promoter later than NF-κB and IKKα.

As shown in Figure 4.10, we have a time course recruitment profile of NF-κB,
Notch-1 and IKKα to the cIAP-2 promoter. At the 1 hr time point, both NF-κB subunits
and IKKα but not Notch-1 are associated with the promoter. Notch-1 is recruited at about
3 hrs after coculture. However, both NF-κB subunits and IKKα recruitments require
Notch-1 presence in the activation mediated by Jagged-1. This suggests that Notch-1 may
activate NF-κB and/or IKKα before being recruited to the promoter. We then started
looking for possible mechanisms through which Notch-1 may activate NF-κB and/or
IKKα. Literature suggests us that Akt might be the IKK upstream kinase responsible for
NF-κB activation mediated by active Notch-1.
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Figure 4.10: NF-κB and IKKα are recruited to the cIAP-2 promoter before
Notch-1.
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Figure 4.10: NF-κB and IKKα are recruited to the cIAP-2 promoter before Notch-1. (AC) MDA-MB-231 cells were cocultured with mouse parental LTK cells (PAR) or LTK
cells with high expression of Jagged-1 (JAG) for the indicated time. ChIP assays against
specific antibodies were performed. All ChIP data were expressed as relative fold
induction of specific antibody over IgG control. All data were normalized to internal
control: unspecific binding to β-globin intron sequence. *P <0.05 compared to LTK-PAR
cocultured. Data are representative of three independent experiments.
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6. NF-κB activation by Jagged-1 correlates with activation of Akt, IKK complex and
IKKα.
Many studies show that Notch-1 activates or is required for activation of Akt
pathway in various systems (Nair et al., 2003; Liu et al., 2006; Graziani et al., 2008;
Meng et al., 2009). Recently, Perumalsamy et al have demonstrated that cytoplasmic but
not nuclear Notch-1 activates Akt to rescue cell apoptosis triggered by nutrition
withdrawal (Perumalsamy et al., 2009).
In addition，NF-κB is an important downstream target of Akt activation. It is
reported that Akt is required for NF-κB activation induced by TNF-α (Ozes et al., 1999).
Akt functions through IKK to promote the transactivation potential and phosphorylation
of NF-κB (Madrid et al., 2001). Akt is proposed to promote metastasis and angiogenesis
through IKK in a manner that depends on NF-κB activation (Agarwal et al., 2005).
Therefore, it is possible that Notch-1 activates IKK and/or IKKα via Akt in LTK-JAG
cocultured cells.
In order to test whether Notch-1 activates IKK and/or IKKα via Akt,
phosphorylation of Akt was determined by western blot. Interestingly, Akt was
phosporylated 15 mins after MDA-MB-231 cells were cocultured with LTK-JAG. IKK
complex were also activated starting from 15 mins coculture and further activated in a
time dependent manner up to 1hr, as evidenced by phosphorylated IKK α/β on serine
180/181. Consequently, the downstream target of IKK complex IκBα was phosphorylated
and degraded beginning from 15 mins to 1hr (Figure 4.11 A). Total IKK and Akt
expression levels were comparable in LTK-PAR and LTK-JAG cocultured cells.
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Phosphorylation of IKKα at serine 180 has been shown to be linked to IKKα
activation and IKKα chromatin associated kinase activity (Hoberg et al., 2004). We
assessed IKKα activation by detecting the phosphorylation of IKKα at serine 180. The
western blots were performed using whole lysates from the mixture of mouse and human
cells. In order to confirm the phosphorylation of IKKα occurs in MDA-MB-231 cells, we
immunoprecipitated IKKα using a human specific antibody. Human specific antibody
failed to immunoprecipitate any IKKα in mouse cells, validating the human specificity
and excluding the cross-reactivity (Figure 4.11 B). Our data show that IKKα was
phosphorylated (activated) in LTK-JAG cocultured MDA-MB-231 cells in a time
dependent manner.
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Figure 4.11: Coculture of MDA-MB-231 cells with LTK-JAG induces activation
of Akt and IKK complex and phosphorylation of IKKα on Serine 180
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Figure 4.11: Coculture of MDA-MB-231 cells with LTK-JAG induces activation
of Akt and IKK complex and phosphorylation of IKKα on Serine 180. (A)
MDA-MB-231 cells were cocultured with LTK-PAR (P) or LTK-JAG (J) for the
indicated time. Western blots were carried out using the whole cell lysates
containing MDA-MB-231 cells and mouse fibroblasts. (B) After coculture, 1000
mg of cell lysates were immunoprecipitated by human specific IKKα antibody.
LTK-PAR cell lysates were immunoprecipitated as a negative control. p-IKKα on
serine 180 and human specific IKKα were immunoblotted following IP. Data are
representative of three independent experiments.
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7. Wortmannin inhibits phosphorylation of IKK complex and IKKα induced by
Notch-1 activation mediated by Jagged-1.

To test if Akt contributes to the phosphorylation of IKK complex and IKKα in the
Jagged-1 induced NF-κB activation pathway, Akt was inhibited by incubating cells with
the PI3K inhibitor wortmannin. Since the half life of wortmannin in the medium is only
10 mins, 50 nM of wortmannin was used 30 mins before, right before and 30 mins after
overlaying LTK cells on a monolayer of MDA-MB-231 cells. As shown (Figure 4.12 A),
Akt activation mediated by Jagged-1 was abolished by addition of wortmannin.
Phosphorylation of IKK and IκBα induced by Jagged-1 was suppressed by wortamannin
incubation, suggesting that Akt is upstream of IKK and IKKα in the NF-κB activation
pathway mediated by Jagged-1. Total Akt, IKK and IκBα expression levels were
comparable in cells treated with or without wortmannin.
Due to the complexity of a mixed coculture of cells from two different species,
the pull down by human specific IKKα antibody was performed to confirm the specificity
of Akt dependence of IKKα phosphorylation in MDA-MB-231 cells (Figure 4.12 B).
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Figure 4.12: Wortmannin inhibits phosphorylation of IKK complex
and IKKα induced by Notch-1 activation mediated by Jagged-1.
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Figure 4.12: Wortmannin inhibits phosphorylation of IKK complex and IKKα induced by
Notch-1 activation mediated by Jagged-1. (A) 50 nM of wortmannin was added to MDA-MB231 cells medium 30 mins before, right before and 30 mins after overlaying LTK cells to a
monolayer of MDA-MB-231 cells. DMSO was used a vehicle control. MDA-MB-231 cells
were cocultured with LTK-JAG in the presence or absence of wortmannin for the indicated time.
Western blots were conducted using the whole cell lysates containing MDA-MB-231 cells and
LTK mouse fibroblasts. (B) After coculture, 1000 mg of cell lysates were immunoprecipitated
by human specific IKKα antibody. p-IKKα on serine 180 and human specific IKKα were
immunoblotted following IP. (C) MDA-MB-231 cells were transfected with either empty vector
(EV) or dominant negative Akt (DN Akt). Forty-eight hrs after transfection, cells were
cocultured with LTK-JAG for 30 mins or 1 hr. Whole cell lysates were used for blotting. Data
are representative of three independent experiments.

Besides pharmacological inhibition of Akt, we also utilized the dominant negative
Akt to manipulate Akt activation. Figure 4.12 C illustrates that activation of Akt induced
by Jagged-1 was abolished in cells transfected with dominant negative Akt. As a result,
phosphorylation of IKK complex was also decreased compared to the control.
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Overexpression of dominant negative Akt was validated by western blot of Akt. This
infers that Akt is responsible for the activation of IKK complex and IKKα in the NF-κB
activity induction mediated by Jagged-1.

8. Wortmannin inhibits the p50, p65, IKKα and Pol II recruitment to the cIAP-2
promoter.

Consistent with the previous observation that Akt is upstream of IKK complex
and IKKα in the NF-κB activation pathway mediated by Jagged-1, wortmannin (Akt
inhibitor) also inhibited the induced recruitment of p50, p65 and IKKα to cIAP-2
promoter (Figure 4.13 A). Pol II occupancy on cIAP-2 promoter was increased
dramatically by LTK-JAG coculture, corresponding to the elevated p50, p65 and IKKα
recruitment and the induction of cIAP-2 transcript. The increased Pol II occupancy was
abrogated by wortmannin as well, confirming the pivotal function of Akt in mediating the
NF-κB activation by Notch-1 (Figure 4.13).
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Figure 4.13: Wortmannin inhibits the p50, p65, IKKα and Pol II
recruitment to the cIAP-2 promoter.
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Figure 4.13: Wortmannin inhibits the p50, p65, IKKα and Pol II recruitment to the
cIAP-2 promoter. (A-B) 50 nM of wortmannin was added to MDA-MB-231 cells
medium 30 mins before, right before and 30 mins after overlaying LTK cells to a
monolayer of MDA-MB-231 cells. DMSO was used a vehicle control. MDA-MB231 cells were cocultured with LTK-PAR and LTK-JAG in the presence or absence
of wortmannin for 1 hr. ChIP assays against specific antibodies were performed. All
ChIP data were expressed as relative fold induction of specific antibody over IgG
control. All data were normalized to the internal control: unspecific binding to βglobin intron sequence. *P<0.05 compared to JAG cocultured. Data are
representative of three independent experiments.

9. Notch-1 activation mediated by EDTA activates the Akt/IKK/NF-κB pathway.

Notch-1 can be activated not only by coculture but also transiently by incubation
with EDTA (Rand et al., 2000). To confirm the activation of NF-κB by Notch-1 and
exclude the possibility that NF-κB activation we observed in coculture experiments was
from mouse fibroblast, we activated Notch-1 signaling by incubating cells with 5 mM
EDTA. Notch-1 was activated and cleaved into active form of Notch-1 even 5 mins after
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addition of EDTA (Figure 4.14 A). Active Notch-1 kept accumulating until 60 mins of
incubation and possibly Notch-1 was modified as indicated by the slight band shift. Akt
was also activated very quickly. Phosphorylation of Akt started 5 mins after addition of
EDTA to the medium. Activation of Akt was transient and disappeared after 30 mins of
incubation. IKK became active 5 mins after EDTA was added and continued to be active
up to 15 mins, in agreement with the activation time profile of Akt. Consistently, IκBα
was phosphorylated about 15 mins after incubation. The coincided activation time
courses of Akt, IKK and IκBα indicate that Notch-1 might activate NF-κB through the
Akt/IKK/IκBα signal transduction cascade.
So far, we have shown that Notch-1 activation induced by either coculture or
EDTA incubation coincided with NF-κB activation through Akt/IKK/IκBα in MDA-MB231 cells. We don’t know if Notch-1 is required for the NF-κB activation mediated by
EDTA. In order to test this, Notch-1 was knocked down by siRNA. In control siRNAtransfected cells, EDTA activated Notch-1 as reflected by the cleaved Notch-1
accumulation determined by western blot. Notch-1 siRNA successfully abrogated the
induction of active Notch-1. Notch-1 siRNA also caused complete abolishment of the
induced phosphorylation of Akt and resulted in decreased phosphorylation of IKK
complex and IκBα, compared to cells transfected with control siRNA (Figure 4.14 B).
These results confirm the requirement of Notch-1 in the activation of NF-κB activity
mediated by EDTA through an Akt/IKK dependent pathway.

103

Figure 4.14: Notch-1 activation mediated by EDTA activates
the Akt/IKK/NF-κB pathway
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Figure 4.14: Notch-1 activation mediated by EDTA activates the Akt/IKK/NF-κB pathway.
MDA-MB-231 cells were incubated with 5 mM EDTA for the indicated time. After incubation,
cells were lysed and western blots were conducted using whole cell lysates. (B) MDA-MB-231
cells were transfected with either Control siRNA (CTL) or Notch-1 (N-1) siRNA. Forty-eight
hrs after transfection, cells were incubated with 5 mM EDTA for the indicated time. Whole cell
lysates were used for blotting. Data are representative of three independent experiments.

10. Akt activation by Notch-1 is independent of CBF-1

It was demonstrated that Notch-1 activation mediated by either Jagged-1 or
EDTA induces Akt activation very transiently. Does cytoplasmic or nuclear Notch-1
activate Akt/IKK/ NF-κB pathway? Does the activation require CBF-1? Given the fact
that the activation of Akt by Notch-1 occurs minutes after stimulation, we hypothesized
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the cytoplasmic Notch-1 activates Akt and this activation doesn’t require CBF-1
involvement. We used the CBF-1 siRNA to block canonical nuclear Notch-1 signaling.
Down-regulation of CBF-1 did not change the phorphorylation status of Akt and IKK
complex. This suggests that cytoplasmic not the nuclear Notch-1 activates Akt/IKK and
Notch-1 doesn’t require CBF-1 to activate Akt/IKK. CBF-1 siRNA reduced the
phosphorylation level of IκBα at 15 mins and 30 mins time points of EDTA incubation,
possibly due to the down-regulated expression of total IκBα (Figure 4.15). The reduction
in total IκBα expression is consistent with our finding in CaSki cells and previous
literature observations (Oakley et al., 2003). These data indicate that Notch-1 regulates
NF-κB activity in a CBF-1 dependent and independent manner.
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Figure 4.15: Akt activation by EDTA is independent of CBF-1
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Figure 4.15: Akt activation by EDTA is independent of CBF-1.
MDA-MB-231 cells were transfected with either Control siRNA
(CTL) or CBF-1 siRNA (CBF). Forty-eight hrs after transfection,
cells were incubated with 5 mM EDTA for the indicated time. Whole
cell lysates were used for immunoblotting. Data are representative of
three independent experiments.
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Interestingly, a function for non-nuclear Notch-1 has been reported in other
systems. In T-cells, it is reported that NIC forms a cytoplasmic complex with PI3K and
the non-receptor protein tyrosine kinase p56Lck to activate Akt (Sade et al., 2004).
Recently, Perumalsamy et al have demonstrated that cytoplasmic but not nuclear Notch-1
activates Akt to rescue cell apoptosis triggered by nutrition withdrawal (Perumalsamy et
al., 2009). Consistent with their data, here, our results suggest that cytoplasmic Notch-1
activates Akt independent of CBF-1.

11. Conclusion of Aim 3

In Aim 3, we have shown that NF-κB was activated by Notch-1 through
Akt/IKK/NF-κB axis. First, we showed that Notch-1 and IKKα were both essential for
basal and stimulated expression of some NF-κB dependent genes. Secondly, we
demonstrated that NF-κB subunits, Notch-1 and IKKα were recruited to NF-κB
dependent gene promoters however, Notch-1 was recruited later than NF-κB subunits and
IKKα, suggesting a Notch-1 function before being recruited to the promoter. We showed
that Notch activation mediated by Jagged-1 activated IKK complex and IKKα, induced
phosphorylation and degradation of IκBα. We found that Akt was upstream of IKK
complex and IKKα in the NF-κB activation pathway mediated by Jagged-1. Inhibiting
Akt pharmacologically or genetically reduced the IKK activation and decreased NF-κB
subunits, Pol II and IKKα recruitment to NF-κB dependent gene promoters. In agreement
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with the data from Notch-1 activation by Jagged-1, Notch-1 activation mediated by
EDTA activated Akt/IKK/NF-κB pathway as well. We proposed that the cytoplasmic, not
the nuclear Notch-1 activates Akt since Akt activation was independent of canonical
nuclear Notch-1 partner CBF-1.

CHAPTER V
DISSCUSSION

A. Notch-1 regulation on NF-κB

The effect of Notch-1 regulation on NF-κB activity has been conflicting. It has
been suggested that Notch-1 inhibits NF-κB activity in the nucleus via direct interaction
mediated by the N-terminal portion of Notch-1 in T cells (Guan et al., 1996; Wang et al.,
2001). Later Osborne group confirmed the interaction between p50/c-Rel and Notch-1 in
T cells, however, they showed that through this interaction, Notch-1 activates the late not
the early NF-κB activity following T cell receptor (TCR) activation by retaining the NFκB subunits in the nucleus and preventing their translocation into the cytoplasm (Shin et
al., 2005).
However, these observed discrepancies in regulation of NF-κB by intracellular
Notch-1 (N1IC) might be due, in part, to the size of the N1IC construct used. The
construct used by Wang and Guan is distinctly different from the physiological, in vivogenerated N1IC. Notch-1 protein is proteolytically cleaved by γ-secretase between amino
acids G1743 and V1744 (Schroeter et al., 1998). Data from Dr.Osborne’s lab indicates
that N1IC effects on NF-κB activity can be vastly different depending on the N1IC
construct used (Cheng et al., 2001; Palaga et al., 2003). Therefore, we expect that size

108

109
discrepancies between active Notch constructs may lead to distinctly different effects
in cells, and may account for the contradictory results previously reported.
In addition, the effect of Notch-1 overexpression on NF-κB highly depends on
Notch-1 expression level and cellular context. Low amounts of Notch-1 stimulate NF-κB
transcriptional activity while higher levels inhibit it as exhibited by Guan (Guan et al.,
1996). We also observed the same effect in cervical cancer as well as in breast cancer
cells, suggesting fine tuning of Notch-1 on NF-κB activity and a complicated regulation
network. In addition to Notch-1 expression level, Notch-1 activation results in inhibition
or activation of NF-κB activity depending on the cell type as well. As shown in our data,
overexpression of Notch-1 induces NF-κB activation in CaSki and MDA-MB-231 cells.
However, enforced expression of Notch-1 inhibits NF-κB activity in primary human
keratinocyte (data not shown). In this thesis, we showed that modest overexpression of
Notch-1 activates NF-κB activity in both cervical cancer CaSki cells and ER- breast
cancer MDA-MB-231 cells.

B. Notch-1 regulation on NF-κB in cervical cancer

A role for Notch signaling in cervical cancer was suggested a decade ago
(Zagouras et al., 1995), but has remained controversial. Both overexpression and loss of
Notch-1 have been documented in cervical cancer. Increased expression of Notch-1 and
Notch ligands were reported (Zagouras et al., 1995; Daniel et al., 1997; Gray et al.,
1999). Low level of Notch-1 was expressed in normal cervical epithelium and higher
level was detected in the membrane and cytoplasm of cells of precancerous cervical
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lesions. Accumulation of Notch-1 and its ligand Jagged-1 and down-regulation of
Manic Fringe, a negative regulator of Notch signaling coincided with the progression of
high-grade precursor lesions to invasive cervical cancers (Schweisguth and Lecourtois,
1998; eeraraghavalu et al., 2004). More importantly, Notch-1 was shown to cooperate
with HPV oncoproteins in transforming immortalized human keratinocytes (Rangarajan
et al., 2001; Ramdass et al., 2006). These cells transfected with E6, E7 and Notch-1 were
able to generate xenograft tumors in nude mice (Chakrabarti et al., 2004).
However, there was some controversy raised by Talora et al. They found that
invasive and metastatic cervical cancers as well as cell lines derived from cervical cancer
did not express Notch-1. Activated Notch signaling leads to growth arrest of cervical
cancer derived cell lines (Talora et al., 2005; Wang et al., 2007).
It is difficult to compare data obtained with different antibodies by different
groups, and immunohistochemistry is hardly quantitative. However，in a later study on a
large quantity of clinical samples, Notch-1, its ligand Jagged-1 and its downstream
targets were observed and were accompanied by activation of NF-κB pathway (Ramdass
et al., 2006). Moreover, Lathion et al showed that the effects of Notch-1 in cervical
keratinocytes are strikingly dose-dependent: high levels of constitutively active Notch-1
suppress E6 and E7 as found by Talora et al, but moderate levels of Notch-1 promote
keratinocyte transformation by E6 and E7.
The data from our lab also indicate that Notch-1 protein is present in most
cervical carcinomas, in agreement with Ramdass et al. (Ramdass et al., 2006) and in
cervical carcinoma lines, in agreement with Lathion et al. (Lathion et al., 2003). Notch-2
and 4 appear to be co-expressed with Notch-1. The pattern of Notch-1 expression appears
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to change from granular and membrane-associated in normal cells to diffuse and
primarily cytoplasmic in cancer cells (Song et al., 2008). This may be responsible for
apparent differences in published reports.
Regardless of the relative levels of Notch-1 compared to normal cells, our lab had
previously shown that complete loss of Notch-1 is incompatible with survival in CaSki
cervical cancer cells in vitro and in vivo (Weijzen et al., 2002; Weijzen et al., 2003). We
now show that endogenously expressed Notch-1 is required to maintain constitutive NFκB activity and modest over-expression of Notch-1 activates NF-κB activity in cervical
cancer CaSki cells and suggest a novel mechanism for activation of this pathway by
Notch-1.
Unlike T-cells, where Notch-1 activates NF-κB complexes primarily by
enhancing their nuclear retention (Shin et al., 2005), in cervical cancer cells Notch-1
functions upstream of IKKα/β and serves as a necessary activation co-factor by forming
a physical complex with it. In Aim 2, we found that Notch-1 appears to activate
IKKα/IKKβ complex kinases activity, leading to phosphorylation of IκBα as illustrated
by Figure 5.1.

Notch-3 has been recently reported to bind and activate IKKα

homodimers in murine thymocytes (Vacca et al., 2006). However, in that system Notch-3
binding results in NIK-independent activation of the cytoplasmic functions of IKKα,
leading to the activation of p52/RelB heterodimers. Whether different Notch homologues
modulate IKKα in different ways (i.e., by activating canonical kinase activity or
promoting its kinase activity of phosphorylating p52/RelB), or alternatively Notch
homologues regulate NF-κB by different mechanism remains to be established.
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In CaSki cells, Notch-1/IKKα containing complexes are detectable in the
nucleus as well. It is unclear whether Notch-1 and IKKα migrate to the nucleus as a
complex or associate in the nucleus. However, later, we found that IKKα recruitment to
NF-κB responsive promoter (Song et al., 2008) is Notch-1 dependent. This suggests that
the two proteins may co-translocate to the nucleus.
The association of Notch-1 and IKKα in the nucleus suggests that Notch-1 may
also activate the nuclear functions of IKKα. In recent years, evidence has been
accumulating that IKKα has a number of nuclear functions within and beyond NF-κB
pathway. These functions include the phosphorylation and activation of the estrogen
receptor α, together with its co-activator protein SRC3 in breast cancer cells (Park et al.,
2005) and phosphorylation and stabilization of the β-catenin oncoprotein (Albanese et al.,
2003; Albanese et al., 2003; Carayol and Wang, 2006), phosphorylation of H3 Ser10 and
phosphorylation of SMRT co-repressor. Through binding to IKKα, Notch-1 could be part
of an IKKα-dependent enhanceosome that activates transcription at NF-κB-responsive,
estrogen-responsive and other sites. Recent finding from our lab showed that Notch-1
activates ER dependent transcription via IKKα in ER+ breast cancer cells as shown in
Figure 5.1. This further confirmed the observation of Notch-IKK complex and suggested
potential critical functional role of Notch-IKK complex not only on NF-κB-responsive
but also on estrogen dependent promoters.
On the other hand, is IKKα required for the canonical, CBF-1 mediated effects of
Notch? The traditional mechanism of transcriptional activation by Notch-1 involves an
exchange of SMRT-containing corepressor complexes for coactivator complexes (Kao et
al., 1998; Lai, 2002; Miele, 2006), much like the transcriptional activation of NF-κB and
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the estrogen receptor. The mechanism whereby Notch-1 displaces SMRT-containing
corepressor complexes from CBF-1 (Kao et al., 1998; Kadesch, 2000) is still unclear.
Moreover, IKKα does associate with the Hes-1 promoter, a quintessential Notch/CBF-1
target, and de-represses it in part by phosphorylating promoter-associated IκBα (Aguilera
et al., 2004). Nuclear IKKα can phosphorylate SMRT not only in association with NF-κB
but also in association with CBF-1 (Fernandez-Majada et al., 2007) (Figure 5.1). This
leads to deregulated activation of Notch-mediated signaling. Our lab showed that, at least
in CaSki cells, IKKα is required for canonical CBF-1 activation (Song et al., 2008). This
may be due to the mechanism that IKKα phosphorylates SMRT on CBF-1 dependent
promoters as described by the Bigas group (Fernandez-Majada et al., 2007) and/or due to
the upregulation of Notch ligands by NF-κB (Bash et al., 1999).
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C. Notch-1 regulation on NF-κB in ER- breast cancer

Unlike in cervical cancer, Notch-1 oncogenic role in breast cancer has been
studied and confirmed by several groups including us. Aberrant activation of Notch
signaling was observed in a large number of human breast carcinomas. Our lab has
confirmed that Notch expression was deregulated in human breast cancer as opposed to
normal and hyperplastic breast cells. Ductal and lobular carcinomas consistently
expressed high levels of Notch-1 and Notch-4 as compared to normal breast tissue, which
expressed Notch-1 at barely detectable levels. Reedijk et al showed that high-level
expression of Notch-1 or Jagged-1 predicted poor overall survival in breast cancer
patients, combination of high level of both indicated even worse outlook. The same group
also showed high level Jagged-1 mRNA and protein predicted poor outcome in breast
cancer and Jagged-1 expression was associated with recurrence in lymph node-negative
breast cancer (Reedijk et al., 2005; Dickson et al., 2007; Reedijk et al., 2008).
Inhibition of Notch by pharmacological agents and molecular means has been
shown to suppress breast cancer growth and promote apoptosis (Leong et al., 2007).
However the molecular mechanism responsible for the apoptosis induction was not
known. In this thesis, we are the first to show that Notch-1 may contribute to cell survival
by activating NF-κB activity in ER- breast cancer. We chose to use MDA-MB-231 cells
as our studying model. Because MDA-MB-231 cells, which are ER- basal phenotype
breast cancer (ER-, PR-, Her2-), harbor the highest level of Notch-1 and Jagged-1 (Rizzo
et al., 2008). Moreover, this type of cancer has higher NF-κB activity compared to ER+
breast cancer cells.
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We found that in CaSki cells Notch-1 modulates NF-κB activity by physically
interacting with the IKK signalosome and regulates its IKK kinase activity. We could not
detect a Notch-1 and IKK interaction in MDA-MB-231 cells. Nevertheless, we
demonstrated that Notch-1 is required and sufficient to activate NF-κB activity in MDAMB-231 cells.
In Aim 3, we found that NF-κB activation induced by Notch mediated through
Jagged-1 or EDTA. Active Notch-1 activated Akt and IKK complex and caused
phosphorylation and degradation of IκBα. Consequently, NF-κB subunits, Pol II, IKKα
and Notch-1 were recruited to NF-κB dependent gene promoters. We also demonstrated
that Akt was upstream of IKK complex and IKKα in the NF-κB activation pathway
mediated by Jagged-1. Inhibiting Akt pharmacologically or genetically reduced the IKK
activation and decreased NF-κB subunits, Pol II and IKKα recruitment to NF-κB
dependent gene promoters. We showed that Akt activation was independent of canonical
nuclear Notch-1 partner CBF-1. It is possible that a cytoplasmic Notch is responsible for
Akt activation. The model from Aim 3 is illustrated in Figure 5.2.
An increasing number of reports demonstrate that Notch interacts with Akt in
various systems. Notch-1 is able to activate Akt and also inhibit Akt activity depending
on the physiological context. In T-cells, Notch-1 has been shown to activate Akt via Src
family protein tyrosine kinase p56lck (Sade et al., 2004). Notch signals promote T-cell
precursors survival through maintenance of cellular metabolism via activation of the
PI3K-Akt signaling pathway (Ciofani and Zuniga-Pflucker, 2005). Active Notch-1
inhibits p53-induced apoptosis and sustains transformation by HPV 16 E6 and E7
oncogenes through a PI3K/Akt dependent pathway (Nair et al., 2003). In melanoma,
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constitutive activation of Notch-1 drives primary melanoma toward a more aggressive
phenotype in vitro and in vivo by activating PI3K/Akt pathway (Liu et al., 2006).
The mechanism by which Notch-1 activates Akt has been studied. Notch-1
activates Akt by decreasing PTEN expression through Hes1 and Myc in TALL cells.
Both Hes-1 and Myc bind and regulate the PTEN promoter, with Hes-1 working as a
strong transcriptional repressor and Myc as a weaker transcriptional activator, so that the
overall output downstream of Notch-1 activation is a controlled downregulation of PTEN
transcripts (Palomero et al., 2007). More recently, Perumalsamy (Perumalsamy et al.,
2009) showed another mechanism where cytoplasmic but not nuclear Notch-1 blocks
apoptosis triggered by nutrition deprivation in HeLa cells through mTOR, Rictor and Akt
dependent signaling. The same effect was also observed in the cytokine deprived
condition in activated T cells. Here, we also showed that Notch-1 activated Akt in a CBF1 independent manner, consistent with Perumalsamy’s finding. However, currently we do
not know how exactly Notch-1 activates Akt. Notch-1 may interact with PI3K or mTOR
in MDA-MB-231 cells. Elucidating the mechanism involved is one of our future
directions.
Not only does Notch-1 regulate Akt, on the other hand, Akt also modulates
Notch-1 signaling. Akt requires Notch-1 to transform melanocytes in vitro and Akt
activates Notch-1 through NF-κB activity (Bedogni et al., 2008). Inhibition of Akt results
in a decreased protein expression of Notch-1 (Calzavara et al., 2008). This is also
confirmed in our lab. Inhibition of Akt by wortmannin or dominant negative Akt led to
decrease in Notch-1 protein expression and CBF-1 dependent transcriptional activity in
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T47D:C42 cells (ER- breast cancer cell line). Activation of Akt by overexpressing
wild type or constitutive active Akt increased Notch-1 expression and activity.
There are intertwined Notch-1 and Akt signaling pathways. It would be very
interesting to elucidate the crosstalk between Notch-1 and Akt as well as their association
with NF-κB pathway.

D. Future directions and possible therapeutic implications

In the future, we would like to determine if there is additive or synergistic
therapeutic effect using combination of GSI and current chemo drugs in vitro and in vivo.
ER- breast cancer is usually more aggressive and more difficult to treat than ER+ breast
cancer. In ER- breast cancer, Notch-1 and NF-κB are constitutively active. ER- breast
cancer cells rely more on Notch-1 and NF-κB activity for survival compared to ER+
breast cancer cells. Here, we found that Notch-1 activates pro-survival NF-κB signaling
pathway via Akt in ER- breast cancer MDA-MB-231 cells. ER- breast cancer is usually
treated with chemotherapy and there is no specific target oriented therapy available. We
are going to determine if inhibiting Notch-1 will sensitize ER- breast cancer cells to
apoptosis induced by chemotherapy in vitro and in vivo. If there is synergistic therapeutic
effect, the outlook of ER- breast cancer could be improved. The GSIs are currently
undergoing clinical trials. It would be very promising to combine GSI and current chemodrugs to treat ER- breast cancer patients.
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E. Conclusions

In summary, we showed that Notch-1 activates NF-κB activity in both cervical
and ER- breast cancer cells. We found that Notch-1 activates NF-κB activity by
interacting with IKKα/β and regulating IKKα/β kinase activity in cervical cancer CaSki
cells (Figure 5.1). We demonstrated that Notch-1 activates NF-κB dependent gene
expression in ER- breast cancer MDA-MB-231 cells through an Akt/IKK dependent
pathway (Figure5.2). We explored similarities and differences in the underlying
mechanisms in the two cell types.

Potentially, this study will provide a molecular

rationale for targeting Notch-1, Akt and NF-κB in cervical and ER- breast cancer in the
clinic.
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Figure 5.2 Notch-1 activates NF-κB
through Akt in MDA-MB-231 cells.
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Figure 5.2 Notch-1 activates NF-κB through Akt in MDA-MB-231 cells. In Aim 3,
we showed that Notch-1 is required and sufficient to activate NF-κB activity in
MDA-MB-231 cells and Notch-1 activates NF-κB through the Akt/IKK dependent
pathway. NF-κB activation induced by Notch mediated through Jagged-1 or EDTA
activates Akt and IKK complex and causes phosphorylation and degradation of
IκBα. There is evidence in the literature that not only does Notch-1 regulate Akt,
on the other hand, Akt modulates Notch-1 signaling. Akt requires Notch-1 to
transform melanocytes in vitro and Akt activates Notch-1 through NF-кB activity.
Inhibition of Akt results in the decreased protein expression of Notch-1.
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